Heiner Wedemeyer
#106,461
Most Influential Person Now
Researcher
Heiner Wedemeyer's AcademicInfluence.com Rankings
Heiner Wedemeyermedical Degrees
Medical
#1345
World Rank
#1672
Historical Rank
Gastroenterology
#15
World Rank
#15
Historical Rank
Heiner Wedemeyerphilosophy Degrees
Philosophy
#4327
World Rank
#6801
Historical Rank
Logic
#1814
World Rank
#2657
Historical Rank
Download Badge
Medical Philosophy
Heiner Wedemeyer's Degrees
- Doctorate Medicine Hannover Medical School
- PhD Gastroenterology Hannover Medical School
Why Is Heiner Wedemeyer Influential?
(Suggest an Edit or Addition)Heiner Wedemeyer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
- Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (2012) (1468)
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
- Treatment of acute hepatitis C with interferon alfa-2b. (2001) (823)
- Treating viral hepatitis C: efficacy, side effects, and complications (2006) (697)
- Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection1 (2002) (683)
- Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005) (642)
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis (2007) (618)
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. (2017) (546)
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor (2009) (544)
- Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
- EASL recommendations on treatment of hepatitis C - Final update of the series. (2020) (497)
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
- Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. (1999) (467)
- Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. (2010) (399)
- Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. (2004) (346)
- Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues (2010) (346)
- Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead (2010) (336)
- EASL Clinical Practice Guidelines on hepatitis E virus infection. (2018) (329)
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
- Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
- Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
- Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. (2016) (287)
- Pathogenesis and treatment of hepatitis e virus infection. (2012) (279)
- Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (2008) (270)
- Hepatitis E virus infection (2017) (261)
- The green tea polyphenol, epigallocatechin‐3‐gallate, inhibits hepatitis C virus entry (2011) (259)
- Hepatitis delta virus (2011) (258)
- Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
- The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
- Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells (2001) (244)
- Natural history of acute and chronic hepatitis C. (2012) (235)
- Expert opinion on the treatment of patients with chronic hepatitis C (2009) (232)
- Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection (2009) (226)
- Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
- Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta (2014) (217)
- Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients (2010) (215)
- Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells (2015) (213)
- Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience (2006) (197)
- Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
- Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients (2010) (192)
- Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C (2011) (188)
- Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians (2014) (187)
- Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. (2010) (186)
- [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
- Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. (2003) (185)
- Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C (2005) (184)
- [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
- Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis (2012) (174)
- A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. (2014) (167)
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (2011) (167)
- Peginterferon plus adefovir versus either drug alone for hepatitis delta. (2011) (163)
- Hepatitis C virus mutation affects proteasomal epitope processing. (2004) (160)
- Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. (2008) (157)
- Ribavirin treatment of acute and chronic hepatitis E: a single‐centre experience (2013) (155)
- Hepatitis D virus infection—Not a vanishing disease in Europe! (2007) (149)
- Telomerase gene mutations are associated with cirrhosis formation (2011) (146)
- Chronic Hepatitis E in Heart Transplant Recipients (2012) (146)
- Hepatitis E virus (HEV)‐specific T‐cell responses are associated with control of HEV infection (2012) (146)
- Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. (2011) (145)
- Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). (2011) (139)
- Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy (2016) (138)
- In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome (2016) (136)
- High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection (2004) (131)
- Cytotoxic CD4+ T cells in viral hepatitis (2006) (131)
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
- Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
- Estimates on HCV disease burden worldwide – filling the gaps (2015) (120)
- Treatment of chronic hepatitis B. (2010) (120)
- Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. (2010) (118)
- Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A (2009) (118)
- Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells (2011) (113)
- Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
- Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. (2006) (113)
- Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. (2015) (112)
- Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. (2016) (111)
- Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). (2016) (110)
- Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. (2016) (108)
- Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. (2009) (107)
- Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
- The impact of hepatitis E in the liver transplant setting. (2014) (105)
- The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting (2013) (103)
- Compromised function of natural killer cells in acute and chronic viral hepatitis. (2014) (103)
- Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies (2015) (100)
- Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. (2007) (99)
- Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection (2018) (98)
- Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. (1999) (97)
- Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis (2010) (97)
- Long‐term follow‐up after successful interferon therapy of acute hepatitis C (2004) (97)
- Virological and clinical characteristics of delta hepatitis in Central Europe (2009) (96)
- Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. (2013) (96)
- Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany (2011) (95)
- Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. (2009) (95)
- Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. (2014) (94)
- Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. (2016) (93)
- Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients (2013) (91)
- Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. (2008) (89)
- Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. (2011) (88)
- How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. (2010) (86)
- Extra‐hepatic replication and infection of hepatitis E virus in neuronal‐derived cells (2016) (86)
- Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics (2010) (85)
- Treatment of chronic hepatitis C with PEGylated interferon and ribavirin (2002) (83)
- Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. (2018) (81)
- Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. (2006) (81)
- Prothrombotic immune thrombocytopenia after COVID-19 vaccine (2021) (80)
- Hepatitis E in Germany--an under-reported infectious disease. (2014) (79)
- Glucocorticosteroids increase cell entry by hepatitis C virus. (2010) (79)
- A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels (2008) (78)
- Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues (2011) (78)
- Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. (2008) (78)
- Antiviral treatment and liver‐related complications in hepatitis delta (2017) (76)
- Global multi-stakeholder endorsement of the MAFLD definition. (2022) (74)
- The role of zinc in liver cirrhosis. (2015) (74)
- Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. (2009) (73)
- Managing HBV in patients with impaired immunity (2010) (72)
- Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C (2001) (71)
- Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. (2019) (71)
- Treatment Options for Hepatitis Delta Virus Infection (2013) (71)
- Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe (2018) (70)
- Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated “Human Immune System” Mice (2010) (68)
- [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. (2007) (68)
- Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. (2009) (67)
- Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. (2019) (67)
- Recommendations for the management of hepatitis C virus infection among people who inject drugs. (2013) (67)
- Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls (2018) (66)
- GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection (2019) (66)
- Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin (2009) (65)
- Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis (2014) (65)
- Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors (2013) (65)
- Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? (2018) (64)
- Prothrombotic immune thrombocytopenia after COVID-19 vaccination (2021) (63)
- [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
- Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. (2016) (62)
- Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. (2001) (61)
- Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. (2009) (61)
- Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks (2012) (61)
- Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: The Hepatitis Delta International Network (HDIN) (2018) (60)
- Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
- Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication (2016) (59)
- Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. (2016) (59)
- Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. (2012) (59)
- Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (58)
- Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen (2016) (57)
- Long-term outcome of chronic hepatitis B in heart transplant recipients. (1998) (57)
- Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. (2015) (57)
- Prevalence of HBV genotypes in Central and Eastern Europe (2008) (56)
- Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. (2011) (55)
- Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. (2010) (54)
- Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity (2007) (54)
- A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study (2017) (54)
- Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C (2013) (53)
- Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. (2015) (53)
- Hepatitis D revival (2011) (53)
- Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis (2018) (53)
- Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. (2006) (52)
- Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. (2020) (52)
- Hepatitis E Virus Mutations: Functional and Clinical Relevance (2016) (52)
- Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). (2013) (51)
- Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss (2018) (51)
- Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review (2014) (51)
- O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY (2014) (51)
- Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (51)
- Treatment of HBV/HCV coinfection (2010) (51)
- Influenza virus infection as precipitating event of acute-on-chronic liver failure. (2019) (51)
- Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B‐related disease: failure of humoral and cellular immune response (2006) (51)
- Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. (2015) (51)
- A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. (2015) (51)
- Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. (2019) (51)
- Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. (2008) (51)
- HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. (2014) (50)
- Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts (2020) (49)
- Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. (2002) (49)
- 1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN (2012) (49)
- Hepatitis Delta: Immunopathogenesis and Clinical Challenges (2010) (49)
- Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. (2017) (49)
- [Diagnosis of and therapy for hepatocellular carcinoma]. (2013) (49)
- HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. (2018) (48)
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients (2013) (47)
- Development and evaluation of a baseline-event-anticipation score for hepatitis delta (2014) (47)
- Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry (2017) (47)
- Immunopathogenesis of Hepatitis E Virus Infection (2013) (47)
- Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. (2009) (46)
- Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. (2016) (46)
- Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection (2012) (46)
- Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses (2012) (46)
- Is there sufficient evidence to recommend antiviral therapy in hepatitis C? (2014) (46)
- Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles (2011) (46)
- Hepatitis E in HIV‐positive patients in a low‐endemic country (2009) (45)
- Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. (2019) (45)
- Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response (2007) (45)
- HBeAg‐positive hepatitis delta: virological patterns and clinical long‐term outcome (2012) (45)
- 1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY (2012) (44)
- Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health (2020) (44)
- The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C (2013) (44)
- The role of zinc in liver cirrhosis. (2016) (44)
- Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C (2004) (44)
- Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence (2017) (44)
- Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. (2007) (44)
- Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (2006) (44)
- Chronic hepatitis E in hematopoietic stem cell transplant patients in a low‐endemic country? (2012) (44)
- Immunosuppression, liver injury and post‐transplant HCV recurrence (2012) (44)
- Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals (2014) (43)
- Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re‐infection after liver transplantation (2016) (43)
- Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection (2015) (43)
- Prevalence of hepatitis C in a German prison for young men in relation to country of birth (2006) (43)
- Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. (2008) (43)
- Induction of hepatitis C virus (HCV)‐specific T cells by needle stick injury in the absence of HCV‐viraemia (2007) (43)
- Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta (2014) (42)
- Hepatitis E seroprevalence in the Americas: A systematic review and meta‐analysis (2018) (42)
- Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. (2015) (41)
- Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay (2011) (41)
- Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. (2012) (41)
- Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. (2020) (41)
- Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion AWMF-Register-Nr.: 021/011 Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection - (2011) (41)
- Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis (2017) (40)
- Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy (2012) (40)
- High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting (2014) (39)
- Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients (2017) (39)
- Chronic hepatitis E in liver transplant recipients: a significant clinical problem? (2010) (39)
- The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
- ARFI elastography of the spleen is inferior to liver elastography for the detection of portal hypertension. (2011) (39)
- Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function. (2016) (38)
- Clearance of Chronic HCV Infection During Acute Delta Hepatitis (2009) (38)
- Course and treatment of chronic hepatitis E virus infection in lung transplant recipients (2014) (38)
- Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment (2011) (38)
- Clinical Relevance of Transjugular Liver Biopsy in Comparison with Percutaneous and Laparoscopic Liver Biopsy (2009) (37)
- PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). (2020) (37)
- HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response (2016) (37)
- 1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2007) (37)
- HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. (2012) (37)
- Hepatitis E virus infection: multiple faces of an underestimated problem. (2013) (36)
- Enrichment of Regulatory T Cells in Acutely Rejected Human Liver Allografts (2012) (36)
- Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (2014) (36)
- Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. (2004) (36)
- Seroprevalence of antibodies and antigens against hepatitis A–E viruses in refugees and asylum seekers in Germany in 2015 (2017) (36)
- Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. (2004) (36)
- Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?! (2017) (35)
- Hepatitis E virus replication and interferon responses in human placental cells (2018) (35)
- 136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1 (2003) (35)
- Hepatitis C virus enters human peripheral neuroblastoma cells – evidence for extra‐hepatic cells sustaining hepatitis C virus penetration (2011) (35)
- a proof-of-concept Phase 2a clinical trial with Hbv/hdv entry inhibitor Myrcludex B : lb-20 (2014) (35)
- S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ (2018) (34)
- Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents (2012) (34)
- Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. (2007) (34)
- Medication Adherence among Patients with Chronic Diseases: a Survey Based Study in Pharmacies. (2019) (34)
- The German guideline for the management of hepatitis B virus infection: short version * (2008) (34)
- Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. (2014) (33)
- Results of single‐center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin (2013) (33)
- Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. (2014) (33)
- 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection (2020) (33)
- Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies (2015) (32)
- Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. (2012) (32)
- Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis (2019) (31)
- High Prevalence and Significance of Hepatitis D Virus Infection among Treatment-Naïve HBsAg-Positive Patients in Northern Vietnam (2013) (31)
- Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study (2019) (31)
- Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer (2018) (31)
- How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist (2015) (31)
- Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients (2018) (31)
- Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. (2008) (31)
- Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. (2003) (31)
- Creating an effective clinical registry for rare diseases (2016) (31)
- Devil hepatitis D: an orphan disease or largely underdiagnosed? (2018) (31)
- HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. (2017) (30)
- Hepatitis E: an emerging infectious disease in Germany? (2011) (30)
- Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses (2015) (30)
- [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. (2007) (30)
- Hepatitis E virus infection in a hematopoietic stem cell donor (2014) (30)
- The German network of excellence for viral hepatitis (Hep‐Net) (2003) (30)
- Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level (2019) (30)
- Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2014) (30)
- Evaluation of Sound Speed for Detection of Liver Fibrosis (2010) (30)
- Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins (2001) (30)
- Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes (2020) (29)
- High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. (2012) (29)
- HEV-specific T-cell responses are associated with control of HEV infection (2012) (29)
- Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. (2016) (29)
- Successful early sofosbuvir‐based antiviral treatment after transplantation of kidneys from HCV‐viremic donors into HCV‐negative recipients (2019) (29)
- Intravenous ketamine and progressive cholangiopathy in COVID-19 patients (2021) (29)
- HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection (2018) (28)
- Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? (2008) (28)
- Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. (2012) (27)
- Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. (2006) (27)
- The New Era of Interferon-Free Treatment of Chronic Hepatitis C (2015) (27)
- Non‐invasive fibrosis score for hepatitis delta (2017) (27)
- Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. (2009) (27)
- Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. (2022) (26)
- Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. (2001) (26)
- Hepatitis C virus core antigen testing in liver and kidney transplant recipients (2014) (26)
- Kinetics of hepatitis C viral RNA and HCV‐antigen during dialysis sessions: Evidence for differential viral load reduction on dialysis (2008) (26)
- New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye (2012) (26)
- Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. (2017) (26)
- Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment (2012) (26)
- Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
- Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. (2016) (25)
- The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease (2018) (25)
- Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. (2011) (25)
- Successful treatment of fulminant hepatitis B during pregnancy. (2009) (25)
- Hepatology - A Clinical Textbook, Fifth Edition (2014) (25)
- Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. (2020) (25)
- Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C (2015) (25)
- Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection (2014) (25)
- Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting (2015) (25)
- Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. (2017) (25)
- Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease (2014) (25)
- The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. (2011) (25)
- [S3 guideline hepatitis C addendum]. (2015) (25)
- Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study (2018) (24)
- In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. (2015) (24)
- Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. (2005) (24)
- Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review (2020) (24)
- The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
- Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection (2021) (24)
- Steroid treatment for severe acute cryptogenic hepatitis. (2007) (24)
- Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections (2017) (24)
- Adjuvant therapeutic plasma exchange in septic shock (2021) (24)
- GBV‐C coinfection is negatively correlated to Fas expression and Fas‐mediated apoptosis in HIV‐1 infected patients (2008) (24)
- ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials (2014) (24)
- Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals (2018) (24)
- Current and future treatment of hepatitis C. (2001) (23)
- NK Cells in Hepatitis C: Role in Disease Susceptibility and Therapy (2012) (23)
- Hepatitis B Virus Particles Activate Toll‐Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes (2020) (23)
- Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. (2019) (23)
- Intrahepatic long‐term persistence of parvovirus B19 and its role in chronic viral hepatitis (2009) (23)
- Longer survival of liver transplant recipients with hepatitis virus coinfections (2007) (23)
- Hepatitis E: An update on One Health and clinical medicine (2021) (23)
- Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial (2014) (23)
- S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11) (2021) (23)
- Improved outcome of chronic hepatitis B after heart transplantation by long‐term antiviral therapy (2006) (23)
- High‐resolution determination of human immune cell signatures from fine‐needle liver aspirates (2015) (23)
- Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. (2020) (23)
- Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. (2020) (23)
- Acute CMV-Colitis in a Patient with a History of Ulcerative Colitis (2003) (23)
- Natural history: the importance of viral load, liver damage and HCC. (2008) (22)
- BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. (2022) (22)
- 410 FOOD INTAKE INCREASES LIVER STIFFNESS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2009) (22)
- Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy (2018) (22)
- In Situ Characterization of Intrahepatic Non-Parenchymal Cells in PSC Reveals Phenotypic Patterns Associated with Disease Severity (2014) (22)
- Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. (2012) (22)
- Angiopoietin-2 in acute liver failure* (2012) (22)
- Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. (1999) (22)
- Cross‐genotype‐specific T‐cell responses in acute hepatitis E virus (HEV) infection (2016) (22)
- Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. (2014) (22)
- Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-α2b therapy for Acute Hepatitis C (2006) (22)
- Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials (2017) (22)
- Impaired TRAIL‐dependent cytotoxicity of CD1c‐positive dendritic cells in chronic hepatitis C virus infection (2007) (21)
- Combination therapy of chronic hepatitis C: an important step but not the final goal! (1998) (21)
- Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure (2017) (21)
- Rapid Response to Treatment of Autoimmune Hepatitis Associated with Remission at 6 and 12 Months. (2019) (21)
- Polyethylene glycol–interferon: Current status in hepatitis C virus therapy (2002) (21)
- Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta (2020) (21)
- The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection (2014) (21)
- Structural barriers in the context of opiate substitution treatment in Germany - a survey among physicians in primary care (2013) (21)
- The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus–Specific T Cells (2017) (21)
- Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (21)
- 73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE (2008) (21)
- Membranous Budd–Chiari syndrome in Caucasians (2010) (20)
- Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany (2020) (20)
- [Significance of coinfection with hepatitis G virus for chronic hepatitis C--a review of the literature]. (1998) (20)
- Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam (2017) (19)
- Hepatitis: Hepatitis E vaccination—is HEV 239 the breakthrough? (2011) (19)
- Hepatitis Delta and HIV Infection (2012) (19)
- Seroconversion to hepatitis C virus alternate reading frame protein during acute infection (2009) (19)
- 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma (2021) (19)
- Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis (2014) (19)
- Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. (2015) (19)
- Automated low-flow ascites pump in a real-world setting: complications and outcomes (2018) (19)
- Adenosine and IFN‐α synergistically increase IFN‐γ production of human NK cells (2009) (19)
- Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry (2018) (19)
- Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients (2018) (18)
- Safety and performance of liver biopsies in liver transplant recipients (2014) (18)
- Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells (2018) (18)
- Hepatitis C virus infection from the perspective of heterologous immunity. (2016) (18)
- Impact of GB virus C viraemia on clinical outcome in HIV‐1‐infected patients: a 20‐year follow‐up study (2014) (18)
- Hepatitis E in Deutschland – eine unterschätzte Infektionskrankheit (2014) (18)
- Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. (2004) (18)
- Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. (1998) (18)
- Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry (2016) (18)
- Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA (2014) (18)
- 250 24 weeks of monotherapy with pegylated interferon alfa-2B in patients with acute hepatitis C (2003) (18)
- Diagnosis and treatment of acute hepatitis C virus infection. (2012) (18)
- Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. (2010) (18)
- Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis (2014) (18)
- Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? (2005) (18)
- SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B (2017) (17)
- PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
- [Hepatitis E virus infection: a paradigm shift?]. (2010) (17)
- 17 KINETICS OF HBsAg DECLINE IN HBeAg+ CHRONIC HEPATITIS B PATIENTS WITH 3 YEARS OF TELBIVUDINE TREATMENT DURING THE GLOBE STUDY (2009) (17)
- Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy (2012) (17)
- Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection (2014) (17)
- Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. (2012) (17)
- Spontaneous clearance of chronic hepatitis C after liver transplantation: Are hepatitis C virus–specific T cell responses the clue? (2008) (17)
- Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up (2017) (17)
- [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
- Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. (2015) (17)
- Extra-Hepatic Replication and Infection of Hepatitis E Virus in Neuronal-Derived Cells (2016) (17)
- Interferon-α for Patients with Chronic Hepatitis Delta: A Systematic Review of Randomized Clinical Trials (2012) (17)
- Towards interferon-free treatment for all HCV genotypes (2015) (17)
- Effects of cyclosporine on human dendritic cell subsets. (2005) (17)
- Hepatitis C: therapeutic perspectives. (2001) (17)
- Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients (2019) (16)
- [Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature]. (1998) (16)
- Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir (2017) (16)
- Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses. (2010) (16)
- 124 IMPACT OF PNPLA3 (RS738409 C>G) POLYMORPHISM ON FIBROSIS PROGRESSION AND STEATOSIS IN CHRONIC HEPATITIS C (2011) (16)
- The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C (2010) (16)
- Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms (2017) (16)
- Development of a protocol for the quantitative determination of HBeAg using the Elecsys® HBeAg immunoassay (2011) (16)
- Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. (2011) (16)
- The adverse effects of interferon‐free regimens in 149 816 chronic hepatitis C treated Egyptian patients (2018) (15)
- Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH (2021) (15)
- Reversal of Immunity After Clearance of Chronic HCV Infection—All Reset? (2020) (15)
- 1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL (2009) (15)
- HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals (2015) (15)
- Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? (2009) (15)
- Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
- Estimating HCV disease burden – volume 3 (editorial) (2015) (15)
- Gilbert's syndrome and antiviral therapy of hepatitis C. (2009) (15)
- Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. (2021) (15)
- GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients (2021) (15)
- Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study (2020) (14)
- Cost of treating hepatitis C in Germany: a retrospective multicenter analysis (2014) (14)
- Dynamics of CD81 expression on lymphocyte subsets during interferon‐α‐based antiviral treatment of patients with chronic hepatitis C (2006) (14)
- Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
- Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
- Chronic Hepatitis E is associated with cholangitis (2019) (14)
- Diagnostik, Verlauf und Therapie der Hepatitis-B-Virusinfektion - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten in Zusammenarbeit mit dem Kompetenznetz Hepatitis (2004) (14)
- Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
- [Acute hepatitis B: is antiviral therapy indicated? Two case reports]. (2008) (14)
- Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome (2009) (13)
- High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation (2020) (13)
- Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C (2021) (13)
- Akute Hepatitis B - Ist eine antivirale Therapie indiziert? (2008) (13)
- Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. (2016) (13)
- Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury (2020) (13)
- Hepatitis E virus ORF 1 induces proliferative and functional T‐cell responses in patients with ongoing and resolved hepatitis E (2018) (13)
- Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. (2017) (13)
- Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort (2015) (13)
- Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure (2021) (13)
- Automated Nucleic Acid Isolation Methods for HDV viral Load Quantification can Lead to viral Load Underestimation (2019) (13)
- The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care (2020) (13)
- 1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY (2012) (13)
- Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. (2017) (12)
- Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy (2018) (12)
- Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. (2017) (12)
- Hepatitis C Virus Infection T Cells in Chronic + Virus-Specific CD8 Impaired Effector Function of Hepatitis C (2002) (12)
- Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. (2022) (12)
- Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
- Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
- 366 PREVALENCE AND SEVERITY OF KIDNEY DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B IN EUROPE: DATA FROM THE EUROPEAN VIRGIL COHORT (2011) (12)
- Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study (2017) (12)
- 217 ACOUSTIC RADIATION FORCE IMAGING (ARFI) AS A NEW METHOD OF ULTRASONOGRAPHIC ELASTOGRAPHY ALLOWS ACCURATE AND FLEXIBLE ASSESSMENT OF LIVER STIFFNESS (2009) (12)
- Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study (2002) (12)
- GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts (2019) (11)
- Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany (2013) (11)
- 61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION (2008) (11)
- Real‐world effect of ribavirin on quality of life in HCV‐infected patients receiving interferon‐free treatment (2018) (11)
- Hepatitis B infection in heart transplant recipients (2001) (11)
- The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis (2021) (11)
- Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti‐HCV therapy? – authors’ reply (2016) (11)
- Systemic inflammation and immune cell phenotypes are associated with neuro‐psychiatric symptoms in patients with chronic inflammatory liver diseases (2018) (11)
- Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis (2021) (11)
- Therapie der chronischen Hepatitis C mit PEG-Interferon alpha-2b und Ribavirin: 24 Wochen Behandlung sind ausreichend bei HCV-Genotyp 2 und 3 (2003) (11)
- 12 Active immunization after liver transplantation for HBV related liver disease: Failure to induce HBV-specific humoral and cellular immune responses (2004) (11)
- Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E. (2019) (11)
- Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir (2012) (11)
- Analysis and function of delta-hepatitis virus-specific cellular immune responses (2003) (10)
- Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays (2015) (10)
- Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R) (2019) (10)
- Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combinationwith Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial (2018) (10)
- Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study (2017) (10)
- LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study (2019) (10)
- Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation (2021) (10)
- Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection (2020) (10)
- HDV infection rates in northern Vietnam (2018) (10)
- DAA-Induced HCV Clearance does not Restore the Altered Cytokine and Chemokine Milieu in Patients with Chronic Hepatitis C (2016) (10)
- Soluble immune markers in the different phases of chronic hepatitis B virus infection (2019) (10)
- Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation (2018) (10)
- Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. (2007) (10)
- [Costs of guideline-based treatment of hepatitis B patients in Germany]. (2012) (10)
- Autophagy alleviates amiodarone-induced hepatotoxicity (2020) (9)
- Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R) (2021) (9)
- Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. (2005) (9)
- A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection (2017) (9)
- Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (9)
- Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis (2021) (9)
- Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry (2021) (9)
- The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients (2018) (9)
- Autoimmune hepatitis and overlap syndromes (2002) (9)
- Treatment of chronic hepatitis B and the implications of viral resistance to therapy (2008) (9)
- Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis (2020) (9)
- 35 HEPATITIS E AS A ZOONOSIS AND THE RELEVANCE FOR LIVER TRANSPLANT RECIPIENTS (2009) (9)
- Risk factors and seroprevalence of hepatitis E evaluated in frozen‐serum samples (2002‐2003) of pregnant women compared with female blood donors in a Southern region of Brazil (2018) (9)
- Autoimmune hepatitis induction can occur in the liver (2019) (9)
- Flares during long‐term entecavir therapy in chronic hepatitis B (2016) (9)
- Intranuclear inclusions in hepatocellular carcinoma contain autophagy‐associated proteins and correlate with prolonged survival (2019) (9)
- [Diagnosis, progression and therapy of hepatitis-B-virus infection--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]. (2004) (9)
- Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB (2020) (9)
- NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization (2019) (9)
- Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy (2019) (8)
- Acute hepatitis B: is antiviral therapy necessary? Two illustrative case reports (2008) (8)
- Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators (2015) (8)
- Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany (2010) (8)
- Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany (2013) (8)
- Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C? (2013) (8)
- Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism (2015) (8)
- [Expert recommendations: Hepatitis C and transplantation]. (2016) (8)
- Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection (2012) (8)
- and weight-based ribavirin in patients with genotype (2011) (8)
- BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment (2021) (8)
- Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study (2012) (8)
- [German guidelines on diagnosis and therapy of hepatitis B]. (2007) (8)
- Exacerbation of hepatitis E virus infection during anti-TNFα treatment. (2017) (8)
- Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort (2020) (8)
- [Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany]. (2020) (8)
- Clinical Impact of Liver Biopsies in Liver Transplant Recipients. (2017) (8)
- Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C (2014) (8)
- Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial (2022) (8)
- Characterization of two types of intranuclear hepatocellular inclusions in NAFLD (2020) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. (2008) (7)
- HBV‐specific T‐cell responses in healthy seronegative sexual partners of patients with chronic HBV infection (2009) (7)
- Treatment duration in acute hepatitis C: The issue is not solved yet (2006) (7)
- 745 Stopping Long-Term Nucleos(t)ide Analogue Therapy Before Hbsag Loss or Sero-Conversion in Hbeag Negative Chb Patients: Experience From Four Referral Centers in Germany (2011) (7)
- Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients (2012) (7)
- Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity (2015) (7)
- [Knowledge and management of hepatitis B virus infected patients in Germany]. (2012) (7)
- 294 Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis (2003) (7)
- Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience (2020) (7)
- Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers (2019) (7)
- Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment (2015) (7)
- The burden of hepatitis D - defogging the epidemiological horizon. (2020) (7)
- Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
- Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a (2019) (7)
- Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. (2007) (7)
- All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study (2014) (7)
- How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. (2014) (7)
- Incorporation of primary patient‐derived glycoproteins into authentic infectious hepatitis C virus particles (2014) (7)
- Treatment of acute hepatitis C-how to explain the differences? (2006) (7)
- 1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN (2012) (7)
- 479 Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the Hep-Net/international HDV intervention trial (2006) (7)
- Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration (2021) (7)
- Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection (2021) (7)
- Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2018) (7)
- Prospects and Challenges for T Cell-Based Therapies of HCC (2021) (7)
- 1012 TELBIVUDINE-INDUCED HBEAG SEROCONVERSION IN CHRONIC HEPATITIS B (CHB) IS DURABLE DURING 2 YEARS OFF-TREATMENT FOLLOW-UP (2010) (7)
- Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies (2016) (7)
- Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
- Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta (2014) (6)
- Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens (2019) (6)
- Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (2015) (6)
- Simultaneous mitral valve replacement and liver transplantation. (2011) (6)
- Impact on follow‐up strategies in patients with primary sclerosing cholangitis (2022) (6)
- 46 LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA (2013) (6)
- Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy? (2008) (6)
- HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta (2021) (6)
- Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis (2021) (6)
- 806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION (2013) (6)
- Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R) (2016) (6)
- The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries (2010) (6)
- Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial (2015) (6)
- Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication (2016) (6)
- Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. (2008) (6)
- Impaired effector function of HCV-specific CD8+ T cells in chronic hepatitis C virus infection (2001) (6)
- Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis (2015) (6)
- Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection (2001) (6)
- SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. (2019) (6)
- Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance (2022) (6)
- No increased incidence for GB‐virus C infection in a cohort of HIV‐positive lymphoma patients (2011) (6)
- Hepatitis als Reisekrankheit (2004) (6)
- Kompetenznetz Hepatitis (Hep-Net) (2004) (6)
- [Current recommendations for the treatment of chronic hepatitis C]. (2014) (6)
- New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. (2021) (6)
- Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. (2018) (6)
- [Standard treatment of chronic hepatitis B]. (2004) (6)
- Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs) (2019) (6)
- 48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY (2012) (6)
- 322 SHOULD ALL PATIENTS WITH AUTOIMMUNE HEPATITIS BE SCREENED FOR HEV-INFECTION? (2010) (6)
- Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock (2021) (6)
- 1044 EVALUATION OF A NOVEL ULTRASOUND METHOD FOR THE DETECTION OF LIVER FIBROSIS – PROSPECTIVE COMPARISON WITH TRANSIENT DYNAMIC ELASTOGRAPHY AND HISTOLOGY (2010) (6)
- Imprint of unconventional T‐cell response in acute hepatitis C persists despite successful early antiviral treatment (2021) (6)
- Histological and serological features of acute liver injury after SARS-CoV-2 vaccination (2022) (6)
- A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection (2021) (5)
- Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy (2021) (5)
- Comprehensive phenotyping of regulatory T cells after liver transplantation (2015) (5)
- Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. (2009) (5)
- Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response (2016) (5)
- Acute hepatitis C virus infection: to treat or not to treat? (2004) (5)
- Treatment of hepatitis Delta (2013) (5)
- Interferon-based treatment of chronic hepatitis D. (2022) (5)
- Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin: 2048 (2015) (5)
- Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan? (2015) (5)
- Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials (2018) (5)
- 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin: 2016 (2015) (5)
- P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients (2015) (5)
- Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C? (2017) (5)
- Republished paper: Managing HBV in patients with impaired immunity (2010) (5)
- 67 Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061 (2004) (5)
- THU-188-Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R) (2019) (5)
- 333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (2009) (5)
- The hepatitis E virus: a likely cause of extrahepatic diseases! (2016) (5)
- Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
- Article Commentary: Is There a Need for Liver Disease Monitoring in HIV Patients in Africa? (2011) (5)
- T‐cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide (2022) (5)
- [27] DIFFERENTIAL CYTOKINE PATTERN OF HDV-SPECIFIC CELLULAR IMMUNE RESPONSES DISTINGUISHES TREATMENT RESPONDER AND NONRESPONDER TO PEG-IFNa-2a TREATMENT: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2007) (5)
- Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection (2018) (5)
- Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study (2020) (5)
- P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis (2015) (5)
- Rituximab leads to reactivation of hepatitis B in individuals with resolved infection (2009) (5)
- 929 EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION (2009) (5)
- Elevated fractional donor‐derived cell‐free DNA during subclinical graft injury after liver transplantation (2022) (5)
- Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data (2019) (5)
- 793 REAL-LIFE DATA OF TELAPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GT1 IN GERMANY – AN INTERIM ANALYSIS (2013) (4)
- Intravenous ketamine is a risk factor for jaundice in Covid-19 patients (2021) (4)
- [226] LONG-TERM TREATMENT WITH PEG-IFN-ALFAb REDUCES HEPATOCELLULAR INCIDENCE AND PREVENTS CLINICAL COMPLICATIONS IN HEPATITIS C CIRRHOSIS - AN INTERIM ANALYSIS OF A MULTICENTER TRIAL (2007) (4)
- Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) (2019) (4)
- 770 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBsAg LOSS IN HBeAg NEGATIVE CHB PATIENTS: FOLLOW-UP OF LONG TERM RESPONDERS (2013) (4)
- Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T‐Cell Responses in a Mouse Model (2021) (4)
- Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure (2019) (4)
- Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer (2021) (4)
- P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study (2015) (4)
- Telaprevir‐based triple‐therapy in patients with chronic hepatitis C in Germany: a 12‐week interim analysis of real‐life data (2012) (4)
- Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal (2021) (4)
- Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients (2021) (4)
- Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
- 544 A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES (2012) (4)
- Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study (2016) (4)
- Immunological, virological and clinical long-term follow-up after interferon therapy of acute hepatitis C infection (2003) (4)
- Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R) (2020) (4)
- Early on-treatment HDV-RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta (2015) (4)
- Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers (2022) (4)
- 1255 CHRONIC HEPATITIS E IN IMMUNOSUPPRESSED PATIENTS BEYOND LIVER- AND KIDNEY TRANSPLANTATION (2011) (4)
- 932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS (2012) (4)
- Hepatitis B infection in heart transplant patients. (2001) (4)
- Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis (2022) (4)
- 48 ENHANCEMENT OF HEPATITIS C VIRUS ENTRY BY STEROIDS (2009) (4)
- [Hepatitis as a travel disease]. (2004) (4)
- Hepatitis E virus is highly resistant to alcohol-based disinfectants. (2022) (4)
- Weight Gain after IFN-Free Cure of Chronic Hepatitis C: A Potential Concern? (2016) (4)
- Gradual increase in platelets following sustained virological response among patients with HCV-induced advanced hepatic fibrosis (2013) (4)
- Liver transplantation: A new risk factor for intestinal intussusceptions. (2011) (4)
- [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]. (2003) (4)
- 144 REDUCED DOSE AND DURATION OF PEGINTERFERON ALFA-2B + WEIGHT-BASED RIBAVIRIN IN EUROPEAN AND ASIAN GENOTYPE 2 AND 3 CHRONIC HEPATITIS C PATIENTS (REDD 2/3 TRIAL) (2009) (4)
- Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody (2022) (4)
- 1028 RENAL SAFETY AND ANTIVIRAL EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE REFRACTORY PATIENTS WITH HEPATITIS B VIRUS (HBV) MONO-INFECTION (2010) (4)
- 36 Induction of hepatitis C virus specific T cells by needle stick injury in the absence of HCV-viremia (2003) (4)
- Of guinea pigs and men--an unusual case of jaundice. (2010) (4)
- DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies (2020) (4)
- Gender differences in patient receiving liver transplantation for viral hepatitis. (2012) (4)
- Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity (2018) (4)
- 617 E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: Results of a 15-month, placebo-controlled trial (2006) (4)
- Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study (2022) (4)
- Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis (2021) (4)
- Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) (2020) (4)
- Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma (2020) (3)
- Depressionen und Lebererkrankungen: Die Rolle von Mikrobiom und Inflammation (2019) (3)
- 987 HIGH PREVALENCE OF HEPATITIS MARKER IN IMMIGRANT POPULATIONS: A PROSPECTIVE MULTICENTER SCREENING APPROACH IN A REAL WORLD SETTING (2012) (3)
- Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes (2019) (3)
- Impact of HBV coinfection on hepatitis C virus infection: analysis of 3054 anti HCV-positive patients (2001) (3)
- Auswirkungen einer SARS-CoV-2-Infektion auf Symptomatik und Therapie chronisch-entzündlicher Darmerkrankungen (2021) (3)
- Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen (2020) (3)
- Significant compartment‐specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection (2021) (3)
- Current Management of HBV/HDV Coinfection and Future Perspectives (2015) (3)
- Wie lässt sich die Eliminierung von Hepatitis B, C und D in Deutschland messen? Ergebnisse eines interdisziplinären Arbeitstreffens (2020) (3)
- Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. (2020) (3)
- 504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS (2013) (3)
- Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites (2022) (3)
- Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 monoinfection: Final results of the German HepNet Acute HCV IV Study (2016) (3)
- 855 A CLINICAL TRIAL EVALUATING LOW HCVRNA VIREMIA IN PATIENTS TREATED WITH TRIPLE THERAPY REGIMENS: IMPLICATIONS FOR PATIENT MANAGEMENT USING DIFFERENT ASSAYS IN CLINICAL PRACTICE (2013) (3)
- Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience (2021) (3)
- Potential viral triggers for pediatric and adult autoimmune hepatitis (2017) (3)
- The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection (2021) (3)
- Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C (2003) (3)
- P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2014) (3)
- PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis (2019) (3)
- CASE REPORT: A Rare Manifestation of Behçet's Syndrome: Immunological Correlates and Successful Treatment of an Esophageal Ulcer (2003) (3)
- Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. (2020) (3)
- [605] THERAPEUTIC PEPTIDE VACCINATION AGAINST CHRONIC HEPATITIS C VIRUS INFECTION (2007) (3)
- IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis? (2021) (3)
- From volcano clouds to iLivers: EASL growing in times of change. (2011) (3)
- Sustained Virological Response Improves Overall Survival in Chronic Hepatitis C Patients with Advanced Fibrosis (2011) (3)
- Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting (2015) (3)
- Rral-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany – an interim analysis (2013) (3)
- A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction (2020) (3)
- Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study (2015) (3)
- 928 EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS (2009) (3)
- Hepatitis C new drugs (2010) (3)
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma. (2014) (3)
- Safety and Efficacy of IFN- Free Antiviral Therapies in Advanced HCV- Associated Liver Cirrhosis: Results from the German Hepatitis C-Registry (DHC-R) (2016) (3)
- [Hepatitis (Hep-Net) competence network]. (2004) (3)
- Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis. (2015) (3)
- Hepatitis C virus living off the fat of the land (2007) (3)
- O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
- HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination (2020) (3)
- 1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
- Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R) (2018) (3)
- Reverse Inflammaging: Long-term effects of HCV cure on biological age (2022) (3)
- Virushepatitis und Schwangerschaft (1974) (3)
- 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis (2015) (3)
- 1159 SERUM ZINC BUT NOT SERUM VITAMIN D LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND TREATMENT RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2011) (3)
- No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B (2018) (3)
- 160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
- Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (3)
- Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial (2009) (2)
- Influence of PML, RASSF6 and NLRP12 on growth and recurrence of human hepatocellular carcinoma (2020) (2)
- Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients (2020) (2)
- Interferon-free cure of hepatitis C virus infection does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis (2017) (2)
- P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients (2015) (2)
- Clinical evaluation of a novel Fast-track diagnostics multiplex real-time PCR assay for detection and quantification of Hepatitis E virus (2015) (2)
- Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
- P0735 : Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCVRNA assays (2015) (2)
- Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network (2017) (2)
- HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin (2016) (2)
- Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia (2007) (2)
- Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals (2018) (2)
- 857 TRIPLE THERAPY FOR HEPATITIS C VIRUS (HCV) INFECTION IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS: LESSONS LEARNED FROM THE FIRST REAL-WORLD EXPERIENCE (2013) (2)
- Acute hepatitis C infection: Can immunology teach us the right way to treat? (2004) (2)
- Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice (2019) (2)
- Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis (2021) (2)
- Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis (2017) (2)
- Safety and Efficacy of 10 mg Myrcludex B/IFNa Combination Therapy in Patients with Chronic HBV/HDV Co-Infection (2020) (2)
- Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19 (2022) (2)
- Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection (2010) (2)
- 382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX (2011) (2)
- Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany (2021) (2)
- PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study (2019) (2)
- Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2021) (2)
- Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
- No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based regimen in HCV Genotype 1 Treatment-Naive Patients: Subanalysis of C208 Study (2011) (2)
- P0754 : Clinical significance of drug-drug interactions during therapy with novel daas against HCV (2015) (2)
- 364 HBsAg SERUM LEVELS ARE ASSOCIATED WITH THE PHASE OF HBV-INFECTION (2009) (2)
- Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (>70 Yrs): Results from the German Hepatitis C-Registry (2016) (2)
- Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy? (2004) (2)
- Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment (2022) (2)
- 1232 INCREASED HEV SEROPREVALENCE IN PATIENTS WITH AUTOIMMUNE HEPATITIS (2013) (2)
- P209: Near full‐length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure (2015) (2)
- Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program (2013) (2)
- Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis (2015) (2)
- Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. (2020) (2)
- Interim results of a Phase Ib / IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients (2016) (2)
- Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis (2020) (2)
- T cell receptor repertoires within liver allografts are different to those in the peripheral blood. (2020) (2)
- 375 HEPATITIS B SURFACE ANTIGEN CONCENTRATION IN HEPATITIS B/C CO-INFECTION (2009) (2)
- Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta (2022) (2)
- Management of patients coinfected with HBV and HCV (2010) (2)
- 41 S-Collate COHORT ‘REAL-LIFE’ STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE (2013) (2)
- Effect of hepatitis B virus on steatosis in hepatitis C virus co‐infected subjects: A multi‐centre study and systematic review (2018) (2)
- Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance (2021) (2)
- Hepatitis C and Metabolic Disorders: Genetics, Mechanism, and Therapies (Clinical and Experimental) (2012) (2)
- P0638 : Global epidemiology of hepatitis delta: First data from the hepatitis delta international network (2015) (2)
- [PEG-interferons: significance for the treatment of viral hepatitis B and C]. (2001) (2)
- Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. (2012) (2)
- The Effect of Immunosuppression on Coagulation After Liver Transplantation (2019) (2)
- Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
- Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial (2013) (2)
- Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections (2022) (2)
- Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems (2022) (2)
- 455 HCV VIRAL KINETICS DURING RIBAVIRIN MONOTHERAPY: RESULTS OF A RANDOMIZED PARTIALLY DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL (2011) (2)
- O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 (2014) (2)
- 19 ANTIVIRAL EFFECT OF ENTECAVIR: RESULTS FROM 160 CHRONIC HEPATITIS B PATIENTS IN AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (2)
- Late-breaking abstracts (2007) (2)
- Therapie der Hepatitis C (2014) (2)
- S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome (2022) (2)
- Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte (2015) (2)
- Ga-68-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC) (2021) (2)
- Analysis of liver biopsies reveals a strong intrahepatic reduction of HDV and inflammatory markers after treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients (2019) (2)
- Hippo signaling counter regulates early innate immunity in hepatocytes exposed to Hepatitis B virus (2020) (2)
- Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness (2022) (2)
- The INNO-LiPA HBV-DR assay is superior to sequencing for the detection of YMDD-mutants (2003) (1)
- Interruption of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (1)
- Longterm outcome of chronic hepatitis C virus infection in a real-world setting: the German LOTOS study (2011) (1)
- Low Risk of Occult Hepatitis B Infection among Vietnamese Blood Donors (2022) (1)
- Kinetics and predictive value of HBcrAg, HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV‐infected patients (2023) (1)
- P1109 OVERTREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 WITH LOW BASELINE VIRAL LOAD AND RVR: EXPERIENCES IN A REAL WORLD SETTING (2014) (1)
- Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages (2021) (1)
- 313 DYNAMIC FLUCTUATION OF VIROLOGICAL MARKERS DURING THE NATURAL COURSE OF HEPATITIS DELTA (2010) (1)
- Primary sclerosing cholangitis with moderately elevated serum‐IgG4 – characterization and outcome of a distinct variant phenotype (2021) (1)
- Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
- Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. (2023) (1)
- Performance of HCV-Core Antigen Testing in Liver Transplanted Patients: 1030 (2012) (1)
- Partially Restored T Cell Responses in HBEAG-Negative Chronic Patients after Stopping NA therapy (2016) (1)
- PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer (2022) (1)
- Hepatitis B Virus (2004) (1)
- HBV-Infektionen in Deutschland – Versorgungskosten in einem Real-life-Setting (2017) (1)
- Detection of HBV-specific memory T cells in healthy seronegative virus-exposed individuals (2002) (1)
- Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis (2022) (1)
- P1238 SVR24 RATE OF 60% IN HCV G1-INFECTED PRIOR NULL RESPONDERS TREATED WITH MERICITABINE (MCB), BOCEPREVIR (BOC) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R): RESULTS FROM DYNAMO 1 (2014) (1)
- Drei Jahre vertikale Vernetzung im Kompetenznetz Hepatitis : Was können wir aus der Nutzung unterschiedlicher Informationsmedien Lernen? (2006) (1)
- Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS (2021) (1)
- Detection of low HCV viremia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2013) (1)
- Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness (2020) (1)
- Die Kosten der Versorgung von Hepatitis C Patienten in Deutschland (2013) (1)
- Barrieren der Hepatitis-C-Virus (HCV) Elimination in Deutschland: warum erhalten diagnostizierte Patienten keine Therapie? (2020) (1)
- Etablierung und Validierung einer neuen Methode zur HBeAg Quantifizierung in HBeAg positiven Patienten mit chronischer Hepatitis B unter Behandlung mit Telbivudine und Entecavir (2009) (1)
- Securing wider EU commitment to the elimination of hepatitis C virus (2022) (1)
- Nosocomial infections in female compared with male patients with decompensated liver cirrhosis (2022) (1)
- Etablierung einer neuen Ultraschallmethode zur Messung der Lebersteifigkeit – prospektiver Vergleich mit Fibroscan und Leberhistologie (2009) (1)
- Aktuelle Arzneimitteltherapie der Hepatitis C (2018) (1)
- Kinetics of cellular immune responses during the early phase of IFN + ribavirin therapy of chronic hepatitis C infection (2001) (1)
- Induction of innate and adaptive immune responses after stopping NA therapy in HBeAg negative chronic hepatitis B (2015) (1)
- Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir (2017) (1)
- [Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]. (2018) (1)
- P0576 : Impact of organ and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis D virus infection (2015) (1)
- Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis. (2022) (1)
- Reduction of serum infectivity of hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units (2018) (1)
- Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection (2020) (1)
- Neue Therapiestrategien bei viralen Hepatitiden (2004) (1)
- Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant (2020) (1)
- 749 Role of the Cirrhosis Risk Score (CRS) for the Prediction of Fibrosis Progression in Hepatitis C Patients with Minimal Liver Disease (2009) (1)
- UEG Week Vienna 2014 cutting edge symposium: Today’s Science, Tomorrow’s Medicine session features the immune system – a driving force in digestive health and disease (2014) (1)
- [549] INJURY WITH HEPATITIS C (HCV)-CONTAMINATED NEEDLES IN HEALTH CARE WORKERS: WHAT IS THE TRUE RATE OF SEROCONVERSION? (2007) (1)
- The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden (2018) (1)
- Early lamivudine therapy prevents liver failure in patients with fulminant hepatitis B (2002) (1)
- Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals? (2017) (1)
- Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting (2013) (1)
- Cardiogenic shock due to a spontaneously ruptured pheochromocytoma: a rare but life-threatening event—a case report (2022) (1)
- Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters? (2012) (1)
- Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) (2017) (1)
- 744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
- FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study (2019) (1)
- Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany (2021) (1)
- 1033 QUANTITATIVE SERUM HBEAG MONITORING DURING TELBIVUDINE TREATMENT CORRELATES WITH VIROLOGICAL OUTCOMES (2010) (1)
- Correction: Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers (2022) (1)
- Commentary: detection of low level viraemia in telaprevir‐based triple therapy for hepatitis C virus – authors' reply (2014) (1)
- 931 PREDICTION OF LONG-TERM SURVIVAL IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS USING STANDARD LABORATORY TESTS (2012) (1)
- A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection (2022) (1)
- Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. (2021) (1)
- Longterm Benefits of Sustained Virological Response (SVR) in Patients With Chronic Hepatitis C (CHC) Virus Infection: The German Lotos Study (2011) (1)
- Home-Based Management of Refractory Ascites by Permanent Tunneled Peritoneal Catheter is an Effective Replacement for Recurrent Large Volume Paracentesis (2016) (1)
- Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study (2017) (1)
- Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline (2022) (1)
- P671 INCREASED ANTI HEV SEROPREVALENCE RATES IN HEART TRANSPLANT RECIPIENTS: COMPARISON OF TWO SEROASSAYS (2014) (1)
- Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study (2022) (1)
- Effects on health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection – Results from the German Hepatitis C-Registry (DHC-R) (2019) (1)
- Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors (2015) (1)
- Therapie der Hepatitis-C-Infektion (2001) (1)
- Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
- P667 HEPATITIS B CORE-RELATED ANTIGEN (HBcrAg) LEVELS IN THE NATURAL HISTORY OF HEPATITIS B INFECTION IN A LARGE EUROPEAN COHORT (2014) (1)
- Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C (2014) (1)
- Bile acid monitoring to support safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection (2018) (1)
- A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study (2018) (1)
- Treatment of Acute Hepatitis C (2006) (1)
- HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level (2020) (1)
- Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended? (2007) (1)
- A rapid point-of-care device for the diagnosis of Hepatitis Delta Virus infection (2019) (1)
- Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis. (2020) (1)
- Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2023) (1)
- Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum. (2020) (1)
- Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients (2022) (1)
- Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study (2009) (1)
- Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
- [Paradigmatic change in treatment of viral hepatitides]. (2012) (1)
- 711 SERUM CYTOKINE LEVELS DURING PEG-IFNA-2a +/− ADEFOVIR TREATMENT OF DELTA HEPATITIS: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2008) (1)
- 150 – Acute Viral Hepatitis (2012) (1)
- P0668 : On-treatment HBsAg kinetics to predict long-term HDV RNA response to peg-IFNa treatment of hepatitis delta (2015) (1)
- Recombinant Technology Peptide – h 2-microglobulin – MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC – Ig complexes (2002) (1)
- Cytotoxic CD4-positive T cells in viral hepatitis (2004) (1)
- Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis (2011) (1)
- An unusual cause of erythema on both lower legs in a patient with Crohn´s disease. (2021) (1)
- Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered” (2021) (1)
- 62 PHASE II HCVac STUDY OF TG4040 IMMUNOTHERAPEUTIC IN COMBINATION WITH PEGIFNa2a AND RIBAVIRIN IN GENOTYPE 1 CHC TREATMENT NAÏVE PATIENTS: SVR24 FINAL RESULTS (2013) (1)
- Detection of low amounts of HCV-RNA in the serum of sustained virological responders after antiviral therapy (2007) (1)
- Hepatitis-A- und -E-Virus-Infektionen – Altes und Neues (2020) (1)
- Dominance of HCV in HBV/HCV co-infected patients is associated with lower quantitative HBsAg and higher serum IP-10 levels (2013) (1)
- Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures (2022) (1)
- Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy (2019) (1)
- [Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (1)
- P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials (2015) (1)
- Rheumatological Patients are at Risk of Chronic HEV Infection: A Multicentric European Study (2016) (1)
- P0606 : TNF-alpha significantly inhibits hepatitis E virus replication (2015) (1)
- [98] EFFECTOR/MEMORY SUBSETS AND FUNCTIONALITY OF CD4/CD8+ T-CELLS DURING POTENT ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B (CHB) (2007) (1)
- HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection (2022) (1)
- 565 RIBAVIRIN TREATMENT OF HEV INFECTION IN IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS: WHICH PATIENTS NEED ANTIVIRAL THERAPY? (2012) (1)
- Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors (2022) (1)
- Hepatitis B virus: where are we and where are we going? (2004) (1)
- 444 Quasispecies evolution in chronic hepatitis C patients after immunization with the therapeutic vaccine IC41 (2006) (1)
- 358 COMPARING THE LONG-TERM OUTCOME OF HEPATITIS DELTA AND HBV MONOINFECTION: IS HDV-INFECTION REALLY WORSE? (2011) (1)
- Differential cytokine pattern of HDV-specific cellular immune responses: Results from the hep-net/international HIDIT-1 study (2007) (1)
- Adefovir serum levels do not differ between responders and nonresponders (2011) (1)
- The widespread rarity of HBsAg loss in chronic hepatitis B. (2019) (1)
- P043: Injecting drug users (IDUs) are prone to Hepatitis B because of the high risk behaviour. Hepatitis B can be prevented through vaccines but the IDUs and their sexual partners from Kathmandu, Nepal are not getting preventive hepatitis B vaccinations (2015) (1)
- Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis. (2021) (1)
- Serum cytokines and HBsAg decline in patients with acute Hepatitis B Virus (HBV) infection (2013) (0)
- HEV genomic insertions identified in chronic patients enhance viral fitness (2023) (0)
- Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1 (2020) (0)
- Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (0)
- State-of-the-Art Lecture: Treatment of hepatitis C (2009) (0)
- Quantification of Large, Middle and Small Hepatitis B virus (HBV) surface protein (HBsAg) fractions in patients with Hepatitis Delta (2014) (0)
- Chronic hepatitis E in lung transplant recipients (2013) (0)
- IFN-alpha activated NK cells require DNAM-1 for recognition of infected cells during acute HCV infection (2010) (0)
- P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4) (2015) (0)
- Dynamics of natural killer cell responses to hepatitis delta virus infection during the course of interferon alpha treatment (P6070) (2013) (0)
- Patients with chronic HCV and decompensated cirrhosis are at risk for MELD purgatory (2022) (0)
- COMPREHENSIVE IMMUNOPHENOTYPING OF TREGS AND SERUM CYTOKINES MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT PATIENTS (2012) (0)
- E-xchange: Hepatitis E and the Risk of Plasma Products for Organ Transplant Recipients. (2018) (0)
- 292 ASSOCIATION OF HBSAG DECLINE WITH INNATE AND ADAPTIVE IMMUNE RESPONSES DURING ACUTE HEPATITIS B VIRUS INFECTION (2011) (0)
- A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
- 548 UNEXPECTED INCREASE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) CONCENTRATIONS DURING TREATMENT WITH NUCLEOS(T)IDE ANALOGUES 12-24 MONTHS BEFORE VIROLOGICAL BREAKTHROUGH AND RESISTANCE (2012) (0)
- Clinical management of viral coinfections (2010) (0)
- A NOVEL IMMUNOSUPPRESSIVE FUNCTION OF ANTI-IL-2 RECEPTOR ANTIBODIES: IMPAIRMENT OF ANTIGEN UPTAKE AND T CELL STIMULATION OF HUMAN MYELOID DENDRITIC CELLS BY BASILIXIMAB IN VITRO AND IN VIVO (2004) (0)
- Patients with Chronic Hepatitis C Can be Identified by their Gut Microbiota (2016) (0)
- P0073 : Individualizing hbig reinfection prophylaxis after HBV-induced liver transplantation: Results from a mathematical modeling approach based on clinical data (2015) (0)
- 642 CHARACTERISATION OF HEPATITIS C VIRUS ENTRY AND RNA REPLICATION IN CELLS OF CNS ORIGIN (2010) (0)
- Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States (2022) (0)
- Genotype-specific expression system of Hepatitis C Virus glycoproteins for efficient viral particle complementation (2013) (0)
- Frequency and functional analysis of variants of the immunodominant epitope NS3–1073: Relevance for vaccine design (2006) (0)
- [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]. (2021) (0)
- 872 IMPACT OF ANTI-RETROVIRAL AGENTS ON SUSCEPTIBILITY TO AND REPLICATION OF HEPATITIS C VIRUS IN VITRO (2012) (0)
- [Hepatitis E - More than a Rare Travel-Associated Infectious Disease!] (2017) (0)
- P0707 : Differences in the intestinal microbiota in patients with chronic hepatitis C (2015) (0)
- HDV infection rates in northern Vietnam (2018) (0)
- A novel class of glycan-specific human monoclonal antibodies neutralizing the hepatitis E virus (2022) (0)
- Abstract 5412: CCR4+CCR6+Th17 cells suppress autologous CD8+ T cell responses in patients with hepatocellular carcinoma (2012) (0)
- Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance (2012) (0)
- Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (0)
- Relevance of quantitative HBsAg (qHBsAg) during long-term treatment of chronic hepatitis B with nucleos(t)ide analogues (NUCs) (2011) (0)
- P660 THE EFFECT OH HEPATITIS B VIRUS INFECTION ON STEATOSIS IN HEPATITIS C VIRUS COINFECTED PATIENTS: THE BOSTIC STUDY (2014) (0)
- Hippo inactivation drives BMI1-associated proliferative hepatocarcinogenesis in chronic hepatitis B virus infection (2022) (0)
- O.180 Longer survival of liver transplant recipients with hepatitis virus coinfections (2006) (0)
- Diet-refractory NASH in an elderly woman (2020) (0)
- Hepatitis B virus-replicating transgenic mice exhibit a functional but restricted responsiveness to exogenous Tlr3 and Rig-I stimuli (2022) (0)
- Risk Factors and Seroprevalence of Hepatitis E in Pregnant and Non-Pregnant Women in a Southern Region of Brazil (2016) (0)
- Partnering for cure meeting in Stockholm (2015) (0)
- O118 A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRO (2014) (0)
- P1210 PREDICTORS OF SVR24 FOR 1078 PATIENTS WITH SEVERE FIBROSIS OR COMPENSATED CIRRHOSIS: THE INTERNATIONAL TELAPREVIR ACCESS PROGRAM (2014) (0)
- 393 Impaired trail-dependent cytotoxicity of CD1C-positive dendritic cells in chronic hepatitis C virus infection (2004) (0)
- 811 RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (2013) (0)
- IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection (2013) (0)
- Ultrasound detected perihepatic lymphadenopathy and response to inferferon alpha in chronic hepatitis C (1998) (0)
- 284 COMPREHENSIVE PHENOTYPING OF IMMUNE CELLS IN CHRONIC HEPATITIS DELTA (2011) (0)
- 638 PARVOVIRUS B19 INFECTION: EVIDENCE FOR INTRAHEPATIC LONG-TERM PERSISTENCE BUT NO ASSOCIATION WITH DISEASE PROGRESSION IN CHRONIC HEPATITIS C (2008) (0)
- Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". (2016) (0)
- ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Prognostic Implications of Lactate, Bilirubin, and Etiology in German Patients With Acute Liver Failure (2008) (0)
- Reply to the Letter to the Editor: “Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma” (2020) (0)
- Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis (2022) (0)
- Comparison of treatment duration in patients infected with genotype 1/4 between 2003–2007 and 2008–2011 period. (2015) (0)
- A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? (2018) (0)
- Association between low anti-HBc level and lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen negative chronic hepatitis B patients (2022) (0)
- P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKER (2014) (0)
- Famciclovir improves liver histology in immunosuppressed patients with chronic hepatitis B (1998) (0)
- Treatment of Hepatitis E in Solid Organ Transplant Recipients: 1751 (2012) (0)
- P122: Type I interferon elevates co‐regulatory receptor expression on CMV‐ and EBV‐specific CD8 T cells in Chronic Hepatitis C (2015) (0)
- 438 BASELINE AND WEEK 24 HBeAg LEVELS ARE ASSOCIATED WITH TELBIVUDINE TREATMENT RESPONSE IN THE 2410 ROADMAP STUDY IN CHRONIC HEPATITIS B (2013) (0)
- O‐27: Early HCV RNA kinetics predict relapse to sofosbuvir/ribavirin dual therapy (2015) (0)
- Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection (2016) (0)
- Immune Responses in Acute and Chronic Hepatitis C (2007) (0)
- The Hippo signalling is induced by Toll-like receptor 4 activation and regulatory balance innate immune responses in liver cells (2019) (0)
- P722 PERFORMANCE AND VALUE OF IFN-LAMBDA3 AND IFN-LAMBDA4 GENOTYPING IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 IN A REAL WORLD SETTING (2014) (0)
- Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
- Modulation of HCV reinfection by fibroblast growth factor-2 and other non-interferon mediators (2015) (0)
- P0565 : Cytokine patterns of patients with HCV/HBV co-infection (2015) (0)
- [476] PREVALENCE OF HBV GENOTYPES IN CENTRAL AND EASTERN EUROPE (2007) (0)
- Large scale biomarker profiling reveals distinct cytokine and chemokine signatures distinguishing different acute and chronic hepatitis virus infections (2015) (0)
- 346 COMPRISED FUNCTION OF NATURAL KILLER CELLS IN ACUTE AND CHRONIC VIRAL HEPATITIS (2013) (0)
- P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction? (2015) (0)
- Declining HIV Drug Resistance in Europe (2013) (0)
- P069: Risk factors associated with type 2 diabetes mellitus in patients with chronic hepatitis B: a cross‐sectional study with pair‐matched controls (2015) (0)
- From Volcano Clouds to iLivers: Growing EASL in times of change (2010) (0)
- Long-Term HDV-RNA Suppression - HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy (2014) (0)
- Whole genome deep sequencing is superior to sequencing only regions of special interest for the characterization of HDV evolution (2017) (0)
- Brain metabolic and microstructural alterations associated with HCV infection, AIH and PBC. (2021) (0)
- Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E (2017) (0)
- Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response' (2022) (0)
- The HCV drug-rally is ongoing: Simeprevir and Daclatasvir approved by EMA! (2014) (0)
- 433 QUANTIFICATION OF LARGE, MIDDLE AND SMALL HEPATITIS B VIRUS (HBV) SURFACE PROTEIN (HBsAg) FRACTIONS IN PATIENTS WITH ACUTE HEPATITIS B (2013) (0)
- P179: Plasma cytokine and chemokine patterns during PEG‐IFNa‐2a therapy of chronic hepatitis delta (2015) (0)
- FIB-4 and APRI-scores predict survival in patients with transjugular intrahepatic portosystemic stent shunts (2020) (0)
- A novel mid-scale screening assay to identify compounds with anti-HDV activity (2017) (0)
- [465] TRAIL-EXPRESSION ON NK CELL SUBSETS IN RESPONSE TO TYPE-I-INTERFERONS IN VIRAL HEPATITIS (2007) (0)
- P060: Incidence of hepatocellular carcinoma in chronic hepatitis B patients responders to nucleoside analogue treatment (2015) (0)
- Adenosine and interferon alpha synergistically increase IFN-gamma production of PBMC via the A3-receptor (2007) (0)
- Akute Hepatitis C – Therapie mit Interferon α-2b (2002) (0)
- mRNA based expression of Hepatitis E specific neutralizing antibodies in liver cells as therapeutic option (2023) (0)
- Expandable constrained 6 mm transjugular intrahepatic portosystemic shunt: an alternative approach for high-risk patients? (2022) (0)
- Anti-HDV-IgM testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon alfa-2a treatment (2010) (0)
- Inhibition of antigen-specific CD8+ T cell proliferation using peptide pools- Possible mechanisms (2009) (0)
- Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment (2015) (0)
- O314: HCV contributes to the aggravation suppressive activity of natural regulatory T cells and induces the emergence of type 1 regulatory T cells (2014) (0)
- Role of BMI, age and sex for disease severity in acute hepatitis C: Analysis of 254 patients from the German Hep-Net acute HCV cohort (2008) (0)
- Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels (2022) (0)
- Kinetic of Hepatitis B core-related antigen (HBcrAg) levels in chronic hepatitis B during NUC therapy (2015) (0)
- Comprehensive characterization of Mucosal-Associated invariant T (MAIT) cells in patients with hepatitis E virus infection (2022) (0)
- Characterization of in-vitro responses to immune modulation of HBV core 18 -specific vs HBV pol455-specific CD8+ T cells (2021) (0)
- Long-term outcome of hepatitis delta compared to HBV monoinfection (2018) (0)
- P185: Cellular immune responses in persistent hepatitis delta virus infection (2015) (0)
- Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up (2022) (0)
- Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta (2022) (0)
- 45 IMMUNE EVASION OF HEPATITIS DELTA FROM CD8+ T CELL IMMUNE RESPONSE (2013) (0)
- 1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis (2019) (0)
- The role of HDV in the natural history of the persistent HBV infection (2011) (0)
- Factors predicting clinical endpoints in Hepatitis Delta: A retrospective-prospective single center study (2013) (0)
- 547 PERFORMANCE OF HCV-CORE ANTIGEN TESTING IN LIVER TRANSPLANTED PATIENTS (2011) (0)
- Immunopathogenesis of Hepatitis D (2014) (0)
- P0053 : Dinstict intrahepatic cytokine profiles for the differentiaton of acute cellular rejection vs recurrent hepatitis C in liver transplanted patients (2015) (0)
- 426 Dynamics of CD81-expression on lymphocyte subsets during antiviral treatment of patients with chronic hepatitis C (2006) (0)
- P145: Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis during IFN‐free antiviral therapy (2015) (0)
- NK cell responses during direct-acting antiviral treatment of chronic hepatitis C virus infection (2016) (0)
- 317 DISTINCT T CELL RESPONSES AND CYTOKINE PATTERN IN HEPATITIS DELTA (2010) (0)
- The impact of adipokines hormones on HCV life-cycle (2014) (0)
- P095: High‐resolution determination of human hepatic immune cell signatures from fineneedle liver aspirates (2015) (0)
- Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta (2016) (0)
- Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation (2022) (0)
- [540] FREQUENCY AND SIGNIFICANCE OF VERY LOW HCV VIREMIA DETECTED BY A HIGHLY SENSITIVE HCV-RNA ASSAY (2007) (0)
- [Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C]. (2010) (0)
- Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry (2022) (0)
- Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients receiving opioid substitution therapy in the German Hepatitis C-Registry (2016) (0)
- Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program (2014) (0)
- P105: Intestinal microbiota in chronic hepatitis C: Differences in microbial communities in patients with and without liver cirrhosis (2015) (0)
- SIMULTANEUS DETECTION OF OXIDIZED AND NITRATED OLEIC ACID METABOLITES IN PATIENTS WITH CHRONIC LIVER DISEASE (2011) (0)
- Letter from the Editor Dear Colleagues (2014) (0)
- Systemic inflammation and altered NK and T cell activation drive neuro-psychiatric symptoms manifested by chronic hepatitis C and autoimmune patients (2017) (0)
- Endoscopic vacuum-assisted closure therapy for leakage of the lower gastrointestinal tract: multicenter experiences (2022) (0)
- No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta. (2023) (0)
- Diagnostik der Hepatitis C Virus Infektion: Rolle des HCV-Core Antigen Assay (2015) (0)
- Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope (2017) (0)
- Sustained HCV-RNA response and HBs-seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in an HCV/HBV-coinfected patient (2007) (0)
- 193 PROGNOSTIC SERUM BIOMARKERS FOR GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION IN HEPATITIS C PATIENTS (2012) (0)
- Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy (2017) (0)
- 287 COMPREHENSIVE PHENOTYPING OF REGULATORY T CELLS FROM PATIENTS AFTER LIVER TRANSPLANTATION REVEALS DISTINCT T-REG PROPERTIES ASSOCIATED WITH GRAFT HEPATITIS AND REJECTION (2011) (0)
- The application of immunoglobulins after liver transplantation influences the occurrence of donor-specific antibody associated complications (2020) (0)
- Management of hepatitis B virus infection: Impact of migrational background, education and household income (2010) (0)
- Effects of anti-TNF? treatment on Crohn’s disease induced hepatic steatosis (2020) (0)
- 621 LACK OF CORRELATION BETWEEN PD-1 EXPRESSION ON T CELLS AND CLINICAL PARAMETERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2008) (0)
- Individuals with migrational background showed high prevalence of hepatitis marker: A prospective screening approach in primary care centers (2013) (0)
- Author Correction: Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2020) (0)
- Apoptosis sensitivity of hepatocellular carcinoma to sorafenib-based treatment combinations depends on the expression pattern of BH3-only proteins (2022) (0)
- Lack of full re-constitution of exhausted HCV-specific CD8+ T cells following IFN-free DAA therapy is partially reversed upon immune check-point inhibitions during chronic HCV (2017) (0)
- High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis (2017) (0)
- 995 CYTOKINE AND CHEMOKINE PATTERNS IN HEPATIC VEIN SERUM DISTINGUISH PATIENTS WITH ACUTE LIVER FAILURE FROM OTHER LIVER DISEASES (2013) (0)
- HBsAg decline after interrupting nucleos(t)ide analogue therapy in HVeAg-negative chronic hepatitis B (2015) (0)
- IN VITRO AND IN VIVO INVESTIGATIONS ON THE EFFECTS OF CYCLOSPORINE ON HUMAN DENDRITIC CELL SUBSETS (2004) (0)
- 299 EXPRESSION OF THE 2B4 ADAPTOR MOLECULE SAP AS A DETERMINANT FOR CD8+ T CELL FUNCTION AND DYSFUNCTION IN VIRAL HEPATITIS (2011) (0)
- 228 GB-VIRUS-C VIREMIA AFTER LIVER TRANSPLANTATION IS ASSOCIATED WITH BETTER 10-YEAR-SURVIVAL (2008) (0)
- SAT-204-Hepatitis E virus antigen in urine as a useful diagnostic Background and aims: for monitoring infection and detection of recent infection (2019) (0)
- Differential expression of perforin in T-cells during interferon therapy of acute hepatitis C (2006) (0)
- 799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
- Single cell analysis of HCV and heterologous virus-specific CD8+T cell responses in patients with chronic hepatitis C before and after HCV elimination (2023) (0)
- Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis (2022) (0)
- 627 IN VITRO PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS CAN BE INHIBITED BY USING PEPTIDE POOLS (2008) (0)
- Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
- Biomarkers to predict the clinical outcome of hepatitis delta (2015) (0)
- Predictors of Response To Intra-Arterial Vasodilatory Therapy of Non-Occlusive Mesenteric Ischemia In Patients With Severe Shock - Results From A Prospective Observational Study (2022) (0)
- CS1-03 Immunological Effects of Type I Interferons in Hepatitis B Revisited: How Does Interferon Work against HBV? (2009) (0)
- Long-term kinetics of quantitative HBsAg levels during successful oral antiviral therapy of chronic hepatitis B (2007) (0)
- IDDF2019-ABS-0212 Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis (2019) (0)
- 14 Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV (2006) (0)
- 435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA (2013) (0)
- K.02 Re-emerging epidemiology of hepatitis virus infections in Europe? (2008) (0)
- Low Prevalence of HEV Infection and No Associated Risk of HEV Transmission from Mother to Child among Pregnant Women in Vietnam (2021) (0)
- Measurement of IgG4 in bile: A new approach to diagnose IgG4-associated cholangiopathy (2012) (0)
- [Three years of vertical networking in the German Network of Competence on Viral Hepatitis: what can we learn from the usage of different information tools?]. (2006) (0)
- 355 APPLYING HEPATITIS B GUIDELINES IN EUROPE: HOW EXPENSIVE IS A STATE-OF-THE ART MANAGEMENT OF HBV INFECTION? (2011) (0)
- P708 CHRONIC HEPATITIS E – THE SPECTRUM OF HISTOPATHOLOGY (2014) (0)
- P153 NK-CELL FREQUENCY AND PHENOTYPE AFFECT THE OUTCOME OF ACUTE HEPATITIS VIRUS C INFECTION (2014) (0)
- P178: Quantitative HBsAg level and its potential applications in patients with hepatitis D coinfection (2015) (0)
- 760 ENTECAVIR TREATMENT IS EFFECTIVE IN PATIENTS WITH PREVIOUS ADEFOVIR TREATMENT: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (0)
- 527 Cytotoxic CD4+ T cells in viral hepatitis (2004) (0)
- Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe (2018) (0)
- TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis (2022) (0)
- 3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta. (2023) (0)
- Reverse Inflammaging: Biological age is accelerated in chronic HCV patients and decelerates after HCV cure (2022) (0)
- Effect of immunosuppressive drugs on regulatory T cells after liver transplantation (2013) (0)
- 419 INACTIVATION OF HEPATITIS C VIRUS BY DISINFECTANTS AND HEAT (2009) (0)
- Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in Germany (2019) (0)
- P139: Development of treatment model for HIV/HCV co‐infected OST patients as the basis for scaling up access to HCV treatment for key populations in Ukraine (2015) (0)
- [661] ROLE OF THE CD26/ADA/ADENOSINE SYSTEM IN VIRAL AND AUTOIMMUNE CHRONIC LIVER DISEASES (2007) (0)
- Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
- P0767 : Clinical utility of hepatitis C virus core antigen testing in the monitoring of treatment naïve non-cirrhotic patients receiving an all-oral, interferon-free regimien (2015) (0)
- PS-028-Viral escape contributes to the failure of hepatitis D virus-specific CD8+ T-cells and drives evolution of HDV (2019) (0)
- Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair (2022) (0)
- Screening for HCV-specific T cell responses: THE USE OF PEPTIDE POOLS IMPAIR THE PROLIFERATION OF ANTIGEN SPECIFIC CD8 T-CELLS (2008) (0)
- P094: Naturally occuring cross ‐ resistance mutation to boceprevir and telaprevir in a naive chronic hepatitis‐C patient: Presentation of a case (2015) (0)
- 448 Decline of HCV-specific CD8+ T cells during interferon-alpha therapy of acute hepatitis C (HCV): Role of apoptosis vs. differential regulation of chemokine receptors (2006) (0)
- 355 ENHANCED INTERFERON ALPHA-DEPENDENT TRAIL EXPRESSION BUT COMPRISED CYTOKINE PRODUCTION OF NK CELLS IN CHRONIC HEPATITIS C IN RELATION TO THE IL28B GENOTYPE (2013) (0)
- P042: Hepatitis B surface proteins (SHBs, LHBs and MHBs) decline after stopping of nucleos(t)ide analogue therapy in HBeAg‐negative patients (2015) (0)
- Rapid and sustained improvements of liver stiffness values in HCV-infected patients treated with direct-acting antiviral drugs (2016) (0)
- 1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies (2014) (0)
- HIV & Hepatitis News New ARV Drugs: What’s in the Pipeline? 14th EACS Conference in Brussels AIDS Vaccine Congress in Barcelona HIV treatment guidelines 14th European AIDS conference: Update on ART HIV-associated lymphoma: Treatment update The price of antiretroviral therapy (2013) (0)
- EFFICACY AND TOLERANCE OF TENOFOVIR DISOPROXIL FUMARATE PLUS EMTRICITABINE COMBINATION IN PATIENTS WITH CHRONIC HEPATITIS B - A EUROPEAN MULTICENTER STUDY (2010) (0)
- Stigma or social support? Experiences of patients with chronic viral hepatitis in their social environment in Germany (2009) (0)
- Genetic variability of hepatitis delta virus in Turkish and German patients: Implications for cellular immune responses (2003) (0)
- [552] IV DRUG ABUSE IS MORE IMPORTANT FOR LIVER INJURY THAN HEPATITIS C VIREMIA IN YOUNG ANTI-HCV POSITIVE PATIENTS (2007) (0)
- Influence of adipokines on cell entry, replication and virus production of Hepatitis C Virus (2013) (0)
- P199: Mutational analysis of hepatitis E virus ORF1 ‘X‐domain’ identifies an evolutionary conserved macrodomain protein/Appr‐1''‐pase active‐site, critical for viral RNA replication in hepatoma cells (2015) (0)
- 677 FREQUENCY AND T-CELL RECEPTOR (TCR) REPERTOIRE OF HEPATITIS C VIRUS (HCV)-SPECIFIC CD8 T-CELLS IN HCV-SERONEGATIVE INDIVIDUALS (2010) (0)
- Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells are Abundant in HCV-Seronegative Individuals and can Show Cross-Reactivity to Common Pathogens (2016) (0)
- [Acute hepatitis C--therapy with interferon alpha-2b]]. (2002) (0)
- P698 CLINICAL OUTCOME AFTER 2 YEARS FOLLOW-UP IN A COHORT OF EUROPEAN UNTREATED HEPATITIS B (HBV) INFECTED PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY) (2014) (0)
- Sex Specific Differences in Nosocomial Infections in Patients with Decompensated Liver Cirrhosis (2021) (0)
- Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus (2023) (0)
- Broad and cross-genotype-specific T cell responses during acute hepatitis E virus infection (2015) (0)
- Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells (2023) (0)
- 321 ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT (2010) (0)
- Hepatitis E virus replication and interferonresponse in human placental-derived cells (2018) (0)
- Safety Comparison of 12- And 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II: 442 (2014) (0)
- P0581 : Prediction of HBsAg seroclearance and HBsAg seroconversion in a cohort of inactive european hepatitis B (HBV) carriers: A prospective longitudinal study (albatros study) (2015) (0)
- 856 CLINICAL SIGNIFICANCE OF DRUG–DRUG-INTERACTIONS IN THE ERA OF DIRECT ACTING ANTIVIRAL AGENTS AGAINST HEPATITIS C – A REAL-WORLD EXPERIENCE (2013) (0)
- 651 VIROLOGICAL AND CLINICAL PATTERNS OF DELTA HEPATITIS IN CENTRAL EUROPE: A SINGLE CENTER EXPERIENCE WITH 255 PATIENTS (2008) (0)
- Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
- Spontaneous clearance of hepatitis C viremia in the absence of humoral immunity and very low levels of cellular HCV-specific immunity (2006) (0)
- 729 ROLE OF BMI, AGE AND SEX FOR DISEASE SEVERITY IN ACUTE HEPATITIS C: ANALYSIS OF 254 PATIENTS FROM THE GERMAN HEP-NET ACUTE HCV COHORT (2008) (0)
- Hepatitis C virus (HCV)-specific CD8 T-cells in HCV-seronegative individuals: Frequency and T-cell receptor repertoire (TCR) (2011) (0)
- P: 47 Risk of Recurrent Hepatic Encephalopathy (HE) in Patients With Liver Cirrhosis: A German Registry Study (2019) (0)
- EASL transitioning into the new decade. (2010) (0)
- RIGINAL ARTICLES — LIVER , PANCREAS , ND BILIARY TRACT rognostic Implications of Lactate , Bilirubin , and Etiology in German atients With Acute Liver Failure (0)
- Prädiktiver Wert von HCV-RNA Resultaten an frühen Zeitpunkten während der Behandlung mit Ledipasvir/Sofosbuvir von Patienten mit chronischer Hepatitis-C-Virusinfektion vom Genotyp 1: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
- Evaluation therapeutischer Plasmapherese bei donorspezifischen Antikörper assoziierten Komplikationen nach Lebertransplantation (2019) (0)
- Die perkutane Leberblindpunktion als sichere diagnostische Methode mit guter Repräsentativität bei Patienten nach Lebertransplantation (2014) (0)
- Untersuchung des Langzeitverlaufs von Patienten mit einer niedrig-replikativen chronischen Hepatitis B-Infektion, die keine antivirale Therapie erhalten: 2 Jahres-Daten einer deutschen prospektiven Studie (ALBATROS Studie) (2015) (0)
- Transjugulärer intrahepatischer portosystemischer Shunt bei Patienten höheren Alters mit Leberzirrhose und therapierefraktärem Aszites - Wagen oder lieber bleiben lassen? (2020) (0)
- 28. Jahrestagung der Gesellschaft für Gastroenterologie in NRW e. V. (2019) (0)
- Beständigkeit des virologischen Ansprechens zu Nachbehandlungswoche 12 (SVR12) bei HCV-Patienten nach Behandlung mit Ombitasvir/Paritaprevir/r und Dasabuvir mit Ribavirin in deutschen Studienzentren (2016) (0)
- Pharmakokinetik von Meropenem in Aszites und Plasma bei PatientInnen mit nosokomialer spontan bakterieller Peritonitis und Leberzirrhose (2020) (0)
- Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten (2017) (0)
- Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun? (2023) (0)
- Nachweis Hepatitis B spezifischer Immunantworten bei gesunden seronegativen Geschlechtspartnern von Patienten mit chronischer Hepatitis B Infektion (2008) (0)
- Effektivität der „switch“-Strategie auf eine Tenofovir-(TDF)Monotherapie bei Patienten mit Nukleos(t)id-Analoga Resistenz: Eine Langzeitverlaufsdokumentation über bis zu 6 Jahre (2008) (0)
- Detektion von portaler Hypertension durch Elastografie der Milz mittels ARFI ist der Elastografie der Leber unterlegen (2010) (0)
- Zoonotisch übertragene Hepatitis E Virus als Ursache akuter und chronischer Hepatitiden bei Lebertransplantierten in Deutschland (2009) (0)
- Elevated M30 serum levels allow the non-invasive detection of fibrotic NASH in NAFLD with low or intermediate FIB-4 (2023) (0)
- Das Hepatitis C Nichtstrukturprotein 2 ist ein zusätzlicher Angriffspunkt für die durch Ciclosporin A vermittelte Hemmung der HCV RNA Replikation (2009) (0)
- Erfahrungen in der Therapie der Hepatitis E Virusinfektion mit Ribavirin (2012) (0)
- Eine mTor-basierte Immunsuppression vermindert die antivirale Effizienz von NS3/4A- und NS5A-Inhibitoren im HCV-Genotyp 1b in vitro (2018) (0)
- Neue und aktuelle Therapieoptionen bei Hepatitis D (2021) (0)
- Begrenztes Wissen über Hepatitis B und schlechte Durchimpfung von Verwandten von Hepatitis B Patienten in Deutschland (2009) (0)
- Kenntnisse und Versorgung von Hepatitis-B-Infizierten in Deutschland (2012) (0)
- 8-wöchige Behandlung therapienaiver Patienten mit chronischer Hepatitis-C-Virusinfektion vom Genotyp 1 mit Ledipasvir/Sofosbuvir: Daten aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
- Steroide steigern die Hepatitis C Virus Infektiösität durch Modulation des Viruseintritts (2009) (0)
- Hepatitis C Viruskinetik während einer Ribavirin Monotherapie: Ergebnisse einer randomisierten, partiell doppelt blind placebokontrollierten klinischen Studie (2011) (0)
- Givosiran als neue therapeutische Option (2021) (0)
- Impact of non-selective beta-blockers on survival and liver-related complications after TIPS-Insertion (2022) (0)
- Verbesserte Pharmakodynamik und Pharmakokinetik nach intravenöser Applikation von Peg-Interferon alfa-2a bei Patienten mit Hepatitis C Genotyp 1 und Null Response auf eine Therapie mit Peg-Interferon alfa/Ribavirin (IVAN-Studie) (2013) (0)
- Prognostische Biomarker für den Langzeitverlauf von Hepatitis Delta (2015) (0)
- Hepatitis E – mehr als nur eine seltene Reisekrankheit! (2017) (0)
- Akkurate und flexible Messung der Lebersteifigkeit mittels einer neuen Ultraschalltechnologie (ARFI) (2009) (0)
- Hepatitis D (2020) (0)
- Virale Hepatitiden: Andere virale Infektionen (2016) (0)
- Therapie der Hepatitis C in Deutschland. Ergebnisse aus dem Deutschen Hepatitis C-Register 4 Jahre nach Zulassung der neuen direkt-antiviralen Substanzen (DAAs) (2018) (0)
- LÄNGERES 10-JAHRES-ÜBERLEBEN VON LEBERTRANSPLANTIERTEN MIT AKTIVER GB-VIRUS-C INFEKTION (2007) (0)
- Virusinaktivierung im Krankenhaus – wie stabil ist das Hepatitis C Virus? (2009) (0)
- Therapie der Hepatitis C in Deutschland nach Zulassung der neuen direkt-antiviralen Substanzen: Erste Ergebnisse aus dem Deutschen Hepatitis C-Register (2015) (0)
- Eingeschränkte TRAIL-abhängige Zytotoxizität myeloider dendritischer Zellen bei der chronischen Hepatitis C (2015) (0)
- Die Elastografie der Milz mittels ARFI ist der Elastografie der Leber bei der Detektion von portaler Hypertension unterlegen (2009) (0)
- Elastografie der Leber mittels einer neuen Ultraschalltechnologie (ARFI) (2010) (0)
- Rolle der Hepatitis-B-Impfung in der Prävention des hepatozellulären Karzinoms (2021) (0)
- Evaluation der Sicherheit und Verträglichkeit einer Tenofovir DF (TDF) Langzeit-Monotherapie bei Nukleos(t)id-Analoga-erfahrenen Patienten mit HBV Monoinfektion (2009) (0)
- Statine bei Lebererkrankungen (2022) (0)
- Detektion von portaler Hypertension durch Elastographie der Milz mittels ARFI ist der Elastographie der Leber unterlegen (2010) (0)
- Deutsches Hepatitis C-Register: Aktuelle Auswertungen und ihre Konsequenzen (2018) (0)
- Beeinflusst die UDCA-Therapie von PBC-Patienten inflammatorische Serumproteine? (2021) (0)
- Von der Transmission bis zur Therapie - Hepatitis A und Hepatitis E - Epidemiologie und natürlicher Verlauf (2005) (0)
- Ursodeoxycholsäure plus Bezafibrat bei PBC (2018) (0)
- Fehlende Korrelation zwischen PD-1 Expression auf T-Zellen und klinischen Parametern in Patienten mit chronischer Hepatitis C Infektion (2008) (0)
- DGVS Jahresrückblick 2021 (2021) (0)
- Factors positively correlated with HBs seroconversion in chronic hepatitis B – a single center experience in a German cohort of 387 patients (2019) (0)
- Virale Infektionen bei Lebertransplantierten (2020) (0)
- Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion? (2022) (0)
- Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern (2021) (0)
- Eine DAA Therapie vor Lebertransplantation hat keinen Einfluss auf das HCC Rekurrenz Risiko nach Lebertransplantation (2018) (0)
- Sind sich Jugendliche über die Gefahren einer Hepatitis-B-Virusinfektion als Geschlechtskrankheit bewusst? (2012) (0)
- Virale Hepatitiden – nach wie vor häufig und wichtig! (2021) (0)
- Transglutaminase-2-Inhibitor zur Therapie der Zöliakie (2021) (0)
- Die Grenzen des G-DRG-Systems bei der Abbildung von Komplexität in der Universitätsmedizin (2020) (0)
- Prädiktion der Fibroseprogression bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 3 Jahres-Daten einer prospektiven longitudinalen Studie (ALBATROS Studie) (2016) (0)
- Klinischer und virologischer Verlauf einer akuten Hepatits A bei Patienten mit Hepatitis C: Geringes Risiko für eine fulminante Hepatitis und Suppression der HCV-Replikation (2006) (0)
- HBV-Infektion in Deutschland – wie sind die Real-Life-Kosten? (2016) (0)
- Statine bei Erkrankungen der Leber: Hopp oder top? (2021) (0)
- Effektivität einer Tenofovir DF (TDF) Monotherapie in Abhängigkeit vorbestehender HBV-Resistenzmusterstationen bei Nukleosid/Nukleotid-Analoga-vorbehandelten Patienten (2009) (0)
- Klinische Evaluation der ARFI-Elastografie mit der linearen Sonde (L9–4MHz): Vergleich mit der konvexen Sonde (C4–1MHz) und dem Fibroscan® zur Beurteilung der Leberfibrose bei Patienten mit chronischer HCV-Infektion (2013) (0)
- Mortalität und ökonomische Auswirkungen der hepatischen Enzephalopathie bei Leberzirrhose in deutschen Krankenhäusern auf der Basis von G-DRG-Kostendaten (2019) (0)
- Betablocker bei kompensierter Zirrhose (2019) (0)
- EInfluss antiretroviraler Medikamente auf das Hepatitis C Virus (2013) (0)
- Natürlicher Verlauf und Therapie der chronischen Hepatitis D (2007) (0)
- Die frühe HDV-RNA Kinetik ist nicht prädiktiv für ein langfristiges Ansprechen auf eine PEG-Interferon-alpha-2a Therapie der Hepatitis Delta (2014) (0)
- Erhöhte Komplikationsrate bei Patienten mit Donorspezifischen Antikörpern nach Lebertransplantation (2018) (0)
- Intra-host diversity of hepatitis E virus polymerase during sofosbuvir treatment (2023) (0)
- HBV-spezifische zelluläre Immunantworten bei der okkulten Hepatitis B nach Lebertransplantation (2006) (0)
- Sodium taurocholate cotransporting polypeptide (hNTCP) Varianten beeinflussen den HDV Zelleintritt aber nicht den antiviralen Effekt von Myrcludex-B (2018) (0)
- P121: Comparative proteomic analysis reveals alterations of Sec61 ER‐translocon at the acute and chronic stages of hepatitis C virus infection in a cell‐based reporter system (2015) (0)
- PCR-Testung von Biopsien und Blutproben von lebertransplantierten Patienten mit „Graft Hepatitis“ auf CMV, EBV und HHV6 (2009) (0)
- Chronische Virushepatitis - Update 2008 (Stand März 2008) (2008) (0)
- Betablocker helfen bei Leberzirrhose (2019) (0)
- Die perkutane Leberblindpunktion ist eine sichere diagnostische Methode mit guter Repräsentativität bei Patienten nach Lebertransplantation (2013) (0)
- 590 Economic evaluation of early monotherapy versus delayed combination therapy in patients with acute hepatitis C (2006) (0)
- Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Ledipasvir / Sofosbuvir-Nutzenbewertung gemäß § 35a SGB V des G-BA (2015) (0)
- Erstbeschreibung der T-Zellantwort gegen das gesamte Genom des Hepatitis E Virus (2016) (0)
- Primär sklerosierende Cholangitis als unabhängiger Risikofaktor für das Auftreten von CMV-Infektionen bei Patienten nach Lebertransplantation (2018) (0)
- Virale Infektionen bei Lebertransplantierten (2020) (0)
- Lebertransplantierte als Risikogruppe für sonographisch gesicherte intestinale Invaginationen beim Erwachsenen (2010) (0)
- Klinische Bedeutung der HBs Antigen-Konzentration bei Patienten mit chronischer HBV/HCV-Koinfektion (2009) (0)
- 24 Wochen Therapie mit Pegyliertem Interferon Alfa-2B bei Patienten mit akuter Hepatitis C Infektion (2004) (0)
- Verlauf einer chronischen HCV-Infektion im Verlauf einer akuten Delta Hepatitis (2007) (0)
- HCV — Eine Erkrankung auf dem — Weg zur Eradikation? (2018) (0)
- The Addition of Ribavirin is Associated with a Significantly Reduced Quality of Life in Patients Treated with IFN-Free Direct-Acting Antiviral Therapy (2016) (0)
- Erhöhte HEV-Seroprävalenz bei Patienten mit Autoimmunhepatitis (2010) (0)
- Einsatz von Thrombopoetin-Rezeptor-Agonisten (TPO-RA) vor invasiven Eingriffen bei Patienten mit Leberzirrhose (2022) (0)
- Hepatitis-A- und -E-Virus-Infektionen – Altes und Neues (2020) (0)
- Statine bei Lebererkrankungen: gut oder schlecht? (2020) (0)
- Ein vermeintliches hepatozelluläres Adenom stellt sich als intrahepatische Splenose heraus – ein Fallbericht (2021) (0)
- Einzelnukleotid-Polymorphismen in der Promotorregion von Cyclophilin A haben keinen EInfluss auf den natürlichen Verlauf einer Hepatitis C Virusinfektion (2013) (0)
- Gastroenterologische Komplikationen des Diabetes mellitus: Gastroparese (2021) (0)
- Zytokin- und Chemokinmuster in Serum von hepatischen Venen differenzieren Patienten mit akutem Leberversagen von anderen Lebererkrankungen (2013) (0)
- Die Baseline HCV RNA Viruslast als Entscheidungshilfe für die Behandlungsdauer mit Ledipasvir/Sofosbuvir bei HCV Genotyp-1-Patienten: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
- Aktuelles Management der Hepatitis Delta (2015) (0)
- Sodium taurocholate cotransporting popypeptide variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B (2018) (0)
- Interferon-α-induzierte Reaktivierung einer Sarkoidose bei einer Patientin mit chronischer Hepatitis C (2010) (0)
- Diagnostik und Therapie der Hepatitis Delta: neue Entwicklungen (2012) (0)
- Gesamtfläche spontaner portosystemischer Shunts als unabhängiger Prädiktor (2020) (0)
- Jahrespressekonferenz der DGVS 2021 (2021) (0)
- Caspasen-Aktivität im Serum als prädiktiver Marker für das Therapieansprechen bei chronischer Hepatitis C Virus Infektion (2006) (0)
- Sicherheit und Wirksamkeit direkt antiviraler Substanzkombinationen zur Behandlung der chronischen Hepatitis- C -Virusinfektion bei älteren Patienten (> 70 Jahre): Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
- 568 IMMUNOLOGICAL EVIDENCE FOR RESOLVED HBVINFECTION IN HEALTHY SERONEGATIVE SEXUAL PARTNERS OF PATIENTS WITH CHRONIC HBV INFECTION (2008) (0)
- Patienten mit chronischer Hepatitis B nach Herztransplantation: Outcome nach 8-jähriger sequentieller Behandlung mit Nukleos(t)id-Analoga (2005) (0)
- Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells (2020) (0)
- Telomerasemutationen sind mit der Entstehung von Leberzirrhose assoziiert (2010) (0)
- Prävalenz der HBV-Genotypen in Mittel–und Osteuropa (2007) (0)
- Können Sie das Wort COVID noch hören? (2021) (0)
- Drogenkonsum ist bedeutsamer für die Leberschädigung bei jungen anti-HCV positiven Patienten als die HCV Virämie (2006) (0)
- Parvo-Virus B19 Infection: Evidence for intrahepatic long-term persistence but no association with disease progression in chronic hepatitis C (2008) (0)
- Die HBsAg-Konzentration ist ein signifkanter Prädiktor für den Krankheitsverlauf bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV)-Infektion (2013) (0)
- Elastographie der Leber mittels einer neuen Ultraschalltechnologie (ARFI) (2010) (0)
- Phänotypische Charakterisierung von HCV-spezifischen CD8+ T-Zellen nach HCV-Peptidimpfung vs. akute und chronische Hepatitis C (2006) (0)
- Prädiktion von HBsAg Verlust und HBsAg Serokonversion bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 2 Jahres-Daten einer deutschen prospektiven longitudinalen Studie (ALBATROS Studie) (2015) (0)
- Sicherheit und Wirksamkeit interferonfreier antiviraler Therapien in der Behandlung fortgeschrittener HCV-assoziierter Leberzirrhose: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
- Thrombozytenzahl, Albumin und Bilirubin identifizieren Patienten mit chronischer Hepatitis C Zirrhose mit hohem Risiko für ein Therapieversagen und schwerwiegende Nebenwirkungen während einer Triple-Therapie mit Boceprevir oder Telaprevir (2014) (0)
- Longterm treatment with pegylated interferon-alfa2b reduces hepatocellular carcinoma incidence and prevents clinical complication in hepatitis C liver cirrhosis–an interim analysis of a multicenter trial (2007) (0)
- 2-Jahresdaten der Telbivudin GLOBE Studie: Wirksamkeit, Verträglichkeit und Prädiktoren des Behandlungserfolgs bei HBeAg-negativen Patienten mit chronischer Hepatitis B (2007) (0)
- Bedeutung der Histologie für die Diagnose und Prognose chronischer Lebererkrankungen aus internistischer Sicht (2006) (0)
- Massiver Ikterus unter Interferon/Ribavirinbehandlung bei Hepatitis C: behandeln oder abbrechen? – eine genetische Antwort (2006) (0)
- Seroprävalenz von Antikörpern/Antigen gegen Hepatitisviren A, B, C, D und E bei Flüchtlingen in Deutschland im Jahr 2015 (2016) (0)
- Häufigere spontane Ausheilung einer akuten HCV-Genotyp 3-Infektion (2004) (0)
- Langzeitnachbeobachtung nach IFN-freier Therapie bei fortgeschrittener HCV-assoziierter Leberzirrhose: Kontinuierliche Verbesserung der Leberfunktionsparameter – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
- Pulmonale Komplikationen einer Lebererkrankung sicher erkennen (2019) (0)
- Sequentielle Therapie mit Interferon alfa und Lamivudin als Konzept für die Therapie der chronischen Hepatitis B: Höhere Chance der HBs-Serokonversion? (2006) (0)
- Slow progressive very late-onset LAL-D: the importance of liver biopsy (2020) (0)
- Soluble inflammatory molecules do not completely normalize despite early treatment of acute symptomatic hepatitis C (2020) (0)
- EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock—a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial (2023) (0)
- Letter: the role of direct‐acting anti‐virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus‐induced cirrhosis—Authors' reply (2018) (0)
- NK cells regulate LSEC to promote the HBV-specific T cells response (2020) (0)
- Reaching the unreachable: Strategien für die effektive HCV Behandlung bei Patienten mit fortgesetztem intravenösen Drogengebrauch - eine Real-World Erfahrung (2021) (0)
- Reply (2012) (0)
- The Interplay of antigen and antibody in HEV infection (2023) (0)
- Autoimmune hepatitis in young Somalian men – experience from a German tertiary care center (2023) (0)
- Health related quality of life of patients in opioid substitution therapy at the beginning of hepatitis C treatment - Data from the German Hepatitis C-Registry (2021) (0)
- Liver Transplantation After Organ Donation Due to Hydrogen Sulfide Intoxication: Report of the First Case. (2022) (0)
- Low free triiodothyronine (fT3) is associated with advanced fibrosis in non-alcoholic steatohepatitis (NASH) (2019) (0)
- Prevalence and clinical presentation of HDV infection in Central Europe in relation to country of birth (2007) (0)
- Treatment strategies for patients with decompensated liver cirrhosis due to HCV infection – Antiviral treatment or liver transplantation first? (2018) (0)
- Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry (2021) (0)
- Long-term course of a patient with overlap hepatitis C and IgG4-related cholangitis (2020) (0)
- Viral escape contributes to the failure of hepatitis D virus (HDV)-specific CD8+ T cells and drives population-level evolution of HDV (2019) (0)
- Establishment of a transgenic, single-nodule model of liver cancer in a fibrotic background (2021) (0)
- Hepatic steatosis in Crohn's disease: associations with anti-TNFα treatment, dysbiosis, and FGF-19. (2020) (0)
- Antivirals in Acute Hepatitis C (2011) (0)
- Comment on: Effects of cyclosporine on human dendritic cell subsets. Author's reply (2005) (0)
- Peritoneal cytokines of patients with decompensated liver cirrhosis drive NK and T cells towards an activated phenotype (2021) (0)
- Role of autophagy in amiodarone-mediated hepatotoxicity (2021) (0)
- The differential phenotype and functionality of CMV- and EBV-specific CD8 T cells in patients with chronic hepatitis C is associated with an altered plasma cytokine milieu (2015) (0)
- Improvement of quality of life after TIPS insertion (2021) (0)
- P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases (2023) (0)
- P071: Viral hepatitis A, B and C in an Afro‐Brazilian community ten years after the first epidemiological and molecular survey (2015) (0)
- Diversity of clinical presentation and virological characteristics of hepatitis delta: The hepatitis Delta International network (HDIN) (2016) (0)
- Hepatitis E seroprevalences in pregnant and non-pregnant women in a southern region of Brazil (2016) (0)
- CD103 identifies an ascites-resident NK cell subset with reduced effector capacity that originates in the intestine (2023) (0)
- Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome (2022) (0)
- Cirrhosis and acute-on-chronic liver failure are linked with aberrant expression of co-stimulatory markers on T-cells (2020) (0)
- Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy? (2020) (0)
- Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis (2023) (0)
- Prognostic serum biomarkers for graft survival after liver transplantation in hepatitis C patients (2013) (0)
- Hepatitis D: Looking Back, Looking Forward, Seeing the Reward and the Promise (2023) (0)
- Immunological scars after cure of hepatitis C virus infection: Long-HepC? (2023) (0)
- Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2018) (0)
- Reply to Letter to the Editor. (2017) (0)
- Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study (2022) (0)
- Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta? (2016) (0)
- 397 LONGITUDINAL ANALYSIS OF QUANTITATIVE SERUM HBSAG IN HBV/HIV COINFECTED PATIENTS (2011) (0)
- Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. (2021) (0)
- Diagnosis and managment of membranous Budd-Chiari syndrome (2008) (0)
- P104: Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
- TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD (2022) (0)
- The association of 2B4 up-regulation and SAP down-regulation indicates exhaustion of virus-specific CD8+ T cells (2011) (0)
- IMMUNOSUPPRESSIVE AGENTS AND THEIR INFLUENCE ON HCV RNA REPLICATION AND INFECTIVITY IN VITRO: 1942 (2008) (0)
- PS-030-Cure of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T-cell responses (2019) (0)
- Exacerbation d’infection par le virus de l’hépatite E au cours d’un traitement par anti-TNFα (2017) (0)
- Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. (2023) (0)
- Risk factors for HBV induced liver cirrhosis (2003) (0)
- Distinct profiles and kinetics of soluble inflammatory markers in patients with acute and chronic HCV-infections and SARS-CoV-2-infections: Implications for the long-term consequences of viral infections? (2023) (0)
- Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders (2022) (0)
- Reply: (2006) (0)
- IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells (2015) (0)
- 369 HEPATITIS DELTA VIRUS RNA DETECTION AND QUANTIFICATION: ISSUES WITH STANDARDIZATION AND NEEDS FOR CLINICAL PRACTICE (2011) (0)
- Does Antiviral Treatment Affect the Clinical Long-Term Outcome of Hepatitis Delta? (2016) (0)
- Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 (2023) (0)
- Acute CMV-colitis in a patient with a history of ulcerative colitis. (2003) (0)
- 111 NEW APPROACH FOR THE IDENTIFICATION OF REPLICATION COMPETENT HCV ISOLATES DERIVED FROM PATIENT SERA (2010) (0)
- Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
- Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE) (2023) (0)
- 21 FUNCTIONAL RELEVANT TELOMERASE MUTATIONS ASSOCIATE WITH CIRRHOSIS FORMATION IN PATIENTS WITH CHRONIC LIVER DISEASE (2010) (0)
- Cost of illness of hepatitis c in germany: A retrospective multicenter analysis (2013) (0)
- Impact of steroid withdrawal on subclinical graft injury after liver transplantation: A propensity score-matched cohort analysis (2023) (0)
- ASIC — LIVER , PANCREAS , AND BILIARY RACT lucocorticosteroids Increase Cell Entry by Hepatitis C Virus (0)
- Long-Term Liver-Related Outcomes in Hepatitis B and D Co-Infected Patients in Sweden (2018) (0)
- Update on the Management of HBV-HDV Coinfection (2012) (0)
- 539 TGFB EXPRESSION IN CD4+/CD25+/FOXP3+/CD127LOW CELLS MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT RECIPIENTS (2011) (0)
- Hepatitis C virus genotypes are associated with distinct intestinal microbial community structures (2017) (0)
- 632 Hepatitis C virus infection in a juvenile prison: High prevalence of HCV among immigrants from the former Soviet Union to Germany (2003) (0)
- BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis—a study protocol for a multicenter, randomized, controlled parallel group trial (2023) (0)
- Hepatitis A virus superinfection suppresses hepatitis C virus replication and may lead to spontaneous HCV clearance (2002) (0)
- P1212 USE OF BASELINE FIBROSCAN TO PREDICT EFFICACY AND SAFETY OF TREATMENT FOR 1143 PATIENTS IN THE TELAPREVIR EARLY ACCESS PROGRAMME (2014) (0)
- 86 INDIVIDUAL HIERARCHIES OF CO-STIMULATORY RECEPTORS ON HCV-SPECIFIC CD8+ T-CELLS IN CHRONIC HEPATITIS C (2010) (0)
- complicationsviral hepatitis C: efficacy, side effects, and (2007) (0)
- P140: Drug‐drug interactions with novel all oral interferon free antiviral agents ‐ all issues solved? (2015) (0)
- Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2022) (0)
- Hepatitis E in Haematological Patients in Europe: A Multicentre Study (2016) (0)
- P689 DIFFERENTIATION OF PATIENTS WITH HBeAg NEGATIVE HEPATITIS VERSUS HBeAg NEGATIVE INACTIVE CARRIER STATUS BY SERUM CYTOKINES AND CHEMOKINES (2014) (0)
- Histopathology of chronic Hepatitis E (2015) (0)
- Author Correction: Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2020) (0)
- 897 CONSENSUS RECOMMENDATIONS FOR VIROLOGIC NOMENCLATURE IN DAA CLINICAL TRIALS (2012) (0)
- Virological heterogenity of hepatitis delta among Vietnamese populations (2018) (0)
- HIV Disclosure Measures (2018) (0)
- P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS (2014) (0)
- Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection (2020) (0)
- Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B (2020) (0)
- Significance of HBsAg and HDVRNA levels in patients with delta hepatitis recruited in the Hep-Net/International HDV intervention trial (2006) (0)
- Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (0)
- Successful triple therapy of patients with chronic hepatitis C genotype 1 infection leads to significant improvement of non-invasive liver fibrosis tests (2014) (0)
- Entecavir efficacy and safety in patients >= 50 years of age (2012) (0)
- Abstract 2498: The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies (2015) (0)
- PGI19 Costs and Effects of Dual Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C in Germany (2012) (0)
- MicroRNAs modulate SARS-CoV-2 infection in primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2 (2022) (0)
- 626 COMPREHENSIVE PHENOTYPIC ANALYSIS OF NK CELLS IN ACUTE HEPATITIS C VIRUS INFECTION (2008) (0)
- Adefovir treatment failure is not associated with low serum drug levels (2010) (0)
- Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2022) (0)
- Early on treatment detection of nucelos(t)ide analogue resistant minor variants of Hepatitis B virus (HBV) with ultra deep-pyrosequencing (UDPS) in chronic hepatitis B(CHB) patients (2013) (0)
- Non-Invasive Clinical Scores to Identify Liver Fibrosis in Hepatitis Delta Patients (2016) (0)
- Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus‐related end‐stage liver disease (2014) (0)
- P215: Exacerbation of hepatitis E virus infection during anti‐TNFα treatment (2015) (0)
- Comprehensive phenotyping of natural killer cells in acute and chronic viral hepatitis (2013) (0)
- Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R) (2022) (0)
- O232: Hepatitis E: are serologic tests good enough and reliable? (2013) (0)
- EASL Recognition Awardee for 2014: Prof. Geoff-Dusheiko. (2014) (0)
- Characterization of T cell responses after stopping HBV therapy with nucleos(t)ide analogues (NA) in HBeAg-negative patients (2016) (0)
- In reply. (2015) (0)
- Experimental Hepatitis E Infection in Pigs (2009) (0)
- P103: Effect of endogenous ligands of the high densitiy lipoprotein‐receptor scavenger receptor class B type I on the replication cycle of the hepatitis C virus (2015) (0)
- Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles (2022) (0)
- Hepatitis B vaccine non-response and occult hepatitis B virus infection (2008) (0)
- 819 IMPROVED PHARMACODYNAMICS AND PHARMACOKINETICS AFTER INTRAVENOUS APPLICATION OF PEG-INTERFERON alfa-2a 180 μg IN CHRONIC HEPATITIS C GENOTYPE 1 NULLRESPONDERS TO PEGINTERFERON/RIBAVIRIN. THE IVAN STUDY (2013) (0)
- 84 ADAPTIVE HEV-SPECIFIC T-CELL RESPONSES ARE ASSOCIATED WITH CONTROL OF HEV INFECTION (2011) (0)
- IFN-alpha induced IFN-gamma production of NK cells is not inhibited but enhanced by adenosine (2009) (0)
- Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness (2022) (0)
- Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos (t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients (2022) (0)
- 1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials (2015) (0)
- [Viral hepatitis and pregnancy]. (1974) (0)
- Targeting epigenetic imprints to modulate HBV-specific T cell responses (2023) (0)
- Rapid and Sustained Improvements of Liver Stiffness Values in HCV-Infected Patients Treated with Direct Antiviral Drugs (2016) (0)
- Variants in the human PPIA gene render host cells refractory to hepatitis C virus infection by destabilization of the essential host factor cyclophilin A (2012) (0)
- 334.6: Porcine SLA-Specific Car Treg Enable Xenotransplantation in the Absence of Immunosuppression (2022) (0)
- 404.1: Membrane-Bound IL-2 Improves Expansion, Survival, Phenotype and Function of Car Tregs and Confers Resistance to Calcineurin-Inhibitors (2022) (0)
- 445 Function and phenotype of peptide-vaccine induced HCV specific CD8+ T cells vs. acute and chronic hepatitis C (2006) (0)
- How to interpret borderline HCV antibody test results? A comparative study investigating four different anti-HCV assays (2013) (0)
- 896 INHIBITORY MECHANISM OF PEPTIDE POOLS ON THE PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS (2009) (0)
- SUPPLEMENT (1966) (0)
- P.076 The cost of hepatitis B in Germany (2006) (0)
- Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review (0)
- 467 LONGTERM BENEFITS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) VIRUS INFECTION: THE GERMAN LOTOS STUDY (2011) (0)
- 1240 CHRONIC HEPATITIS E IN LUNG TRANSPLANT RECIPIENTS (2013) (0)
- Chronic hepatitis E in patients with CVID in Germany (2012) (0)
- Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis (2022) (0)
- Telomere shortening is a prognostic factor in chronic hepatitis C virus infection (2008) (0)
- Autophagy alleviates amiodarone-induced hepatotoxicity (2020) (0)
- P918 miRNA BASED SCORE FOR THE CORRECT DIAGNOSIS OF REJECTION VS RECURRENT HEPATITIS C IN LIVER TRANSPLANTED PATIENTS (2014) (0)
- Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R) (2020) (0)
- 416 PREDICTION OF ACTIVE HBV-CARRIER STATUS IN A COHORT OF EUROPEAN UNTREATED HBeAg NEGATIVE PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (2013) (0)
- High tolerance of hepatitis E virus towards alcohol-based disinfectants (2022) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- SAT-437-An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro (2019) (0)
- FRI-370-Application of an extended-release tacrolimus formulation allows dose reduction and stabilizes graft function after liver transplantation (2019) (0)
- Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma (2020) (0)
- O313: How do we treat acute HCV when we don't have any trial data? (2014) (0)
- Characterization of viral replication in different Hepatitis B virus-transgenic mice and its impact on antiviral signalling in vivo (2023) (0)
- 25 INTRAHEPATIC HHV6 DNA LEVELS BUT NOT EBV OR CMV ARE ASSOCIATED WITH GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION (2010) (0)
- BASIC—LIVER, PANCREAS, AND BILIARY TRACT Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus (2010) (0)
- P070: Cytokine patterns of patients with HCV/HBV co‐infection (2015) (0)
- LATE-BREAKER POSTER ABSTRACTS (2012) (0)
- [In Process Citation]. (2014) (0)
- Real-world effectiveness and safety of glecaprevir/ pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis Graphical (2020) (0)
- Hepatitis B surface antigen induces nuclear accumulation of YAP, thereby driving BMI1-associated hepatocarcinogenesis (2022) (0)
- Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals (2017) (0)
- Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study (2022) (0)
- Incidence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and sicca syndrome: a prospektive single-center study (2008) (0)
- HLA-A2 restricted CD8+ T cell immune hierarchy towards full length hepatitis E virus for T cell-based therapy in chronic HEV (2018) (0)
- [284] ADENOSINE AND INTERFERON ALPHA SYNERGISTICALLY INCREASE INTERFERON GAMMA PRODUCTION OF PBMC VIA THE A3-RECEPTOR (2007) (0)
- Qualitiy of life-scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial (2023) (0)
- Liver biopsy post liver transplantation for HCV-related end stage liver disease: Clinical value and risk factors for graft hepatitis and rejection (2013) (0)
- Students’ guide to documentation in clinical trials (2022) (0)
- Table of contents (2017) (0)
- Poor clinical and virological outcome of nucleos(t)ide therapy in HBV/HDV co-infected patients (2020) (0)
- Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study) (2022) (0)
- Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR (2020) (0)
- Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
- P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (0)
- Hepatitis E ORF2 Antigen Levels Differentiate between Acute and Chronic Course of Infection (2016) (0)
- 772 SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYCLOPHILIN A AND THEIR INFLUENCE ON HCVRNA REPLICATION IN VITRO (2011) (0)
- Limited recirculation of cytotoxic NK cells during normal homeostasis in humans (2019) (0)
- Role of the CD26/ADA/adenosine system in viral and autoimmune chronic liver disease (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Heiner Wedemeyer?
Heiner Wedemeyer is affiliated with the following schools:
